DataIntelo has published a latest market research report on Global Cryonics Technology Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The published report explains about the current supply and demand scenario and presents the future outlook of the market in a detailed manner. DataIntelo has applied a robust market research methodology to bestow the new entrants and emerging players with 360 wide-view analysis on the latest advancements and their impacts on the market. It has congregated massive amount of data on the key segments of the market in an easy to understand format. The research report has laid out the numbers and figures in a comprehensive manner with the help of graphical and pictorial representation which embodies more clarity on the market.

You can buy this complete report @ https://dataintelo.com/checkout/?reportId=92114

Report Covers Impacts of COVID-19 to the market.

The on-going pandemic has overhauled various facets of the market. This research report provides the financial impacts and market disturbance on the Cryonics Technology market. It also includes analysis on the potential lucrative opportunities and challenges in the foreseeable future. DataIntelo has interviewed various delegates of the industry and got involved in the primary and secondary research to confer the clients with information and strategies to fight against the market challenges amidst and after COVID-19 pandemic.

Market Segmentation:

Few of the companies that are covered in the report.

PraxairCellulisCryologicsCryothermKrioRusVWRThermo Fisher ScientificCustom Biogenic SystemsOregon CryonicsAlcor Life Extension FoundationOsiris CryonicsSigma-AldrichSouthern Cryonics

Note: Additional companies can be included in the list upon the request.

By Product Type:

Slow freezingVitrificationUltra-rapid

By Applications:

Animal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

By Geographical Location:Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=92114

The research report provides a detailed analysis of the prominent player in the market, products, applications, and regional analysis which also include impacts of government policies in the market. Moreover, you can sign up for the yearly updates on the Cryonics Technology market.

7 Reasons for Buying Cryonics Technology Market Report

If you have any query regarding the report, ask our experts: @ https://dataintelo.com/enquiry-before-buying/?reportId=92114

Below is the TOC of the report:

Cryonics Technology Supply Chain Analysis

Cryonics Technology Pricing Analysis

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo

See the original post here:
Cryonics Technology Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - The Think Curiouser

Recommendation and review posted by Bethany Smith

The COVID-19 Outbreak:Global Antioxidant Supplement Market to witnessed good recovery in growth and projected coverup market sizing during the forecast period (2020-2026). The assessment provides a 360 view and insights outlining the key outcomes of the Antioxidant Supplement market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions. Some of the key players that are part of coverage are NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets

Get Free Sample Copy of This Research Report:https://www.readmarketresearch.com/sample-request/37406-world-antioxidant-supplement-market

On the basis ofProduct, this report displays the production, revenue, price, market share and growth rate of each type:

Medical Grade, Food Grade

On the basis ofApplications, the market has been segmented into:

Medical, Food, Cosmetics

TopCompaniescovered in the report:NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension

Read Full TOC of Antioxidant Supplement Research Study at @www.readmarketresearch.com/industry-report/37406/world-antioxidant-supplement-market

Research Methodology:

Years considered for the study are:Historical year 2016-2019Disreputable year 2020Estimate period** 2020 to 2025 [** unless otherwise stated]

Primary Research:

The primary sources involve the industry experts from the Global Antioxidant Supplement industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Antioxidant Supplement industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology-oriented perspectives.

Table of ContentsGlobal Antioxidant Supplement Market Research Report 2019-2025, by Manufacturers, Regions, Types and Applications

1 Antioxidant Supplement Market Overview1.1 Introduction1.2 Scope1.3 Assumptions1.4 Players Covered1.5 Market Analysis By Type1.5.1 Global Antioxidant Supplement Market Size Growth Rate By Type (2020-2025)1.5.2 1.5.3 1.5.4 1.6 Market By Application1.6.1 Global Antioxidant Supplement Market Share By Application (2020-2025)1.6.2 Application I1.6.3 Application Ii1.6.4 1.7 Study Objectives1.8 Years

2 Executive Summary

3 Antioxidant Supplement Market Analysis By Type (Historic 2016-2019)3.1 Global Antioxidant Supplement Market Size Analysis (USD Million) 2016-20193.1.1 Type I3.1.2 Type Ii3.1.3 Type Iii3.2 Global Antioxidant Supplement Market Share Analysis By Type (%) 2016-2019

4 Antioxidant Supplement Market Analysis By Application (Historic 2016-2019)4.1 Global Antioxidant Supplement Market Size Analysis (USD Million) 2016-2019

5 Antioxidant Supplement Market Analysis By Regions (Historic 2016-2019)5.1 Global Antioxidant Supplement Market Size Analysis (USD Million) 2016-20195.1.1 Antioxidant Supplement Market Share By Regions (2016-2019)5.1.2 United States5.1.3 Europe5.1.4 China5.1.5 Japan5.1.6 India5.1.7 Rest Of The World

6 Key Companies Analysis/Company Profile

Continued..

Buy the Up-to-date Full Report @www.readmarketresearch.com/checkout?buynow=37406

Key Questions Answered by Antioxidant Supplement Market Report

1. What was the Antioxidant Supplement Market size in 2018 and 2019; what are the estimated growth trends and market forecast (2020-2025).2. What will be the CAGR of Antioxidant Supplement Market during the forecast period (2020-2025)?3. Which segments (product type/applications/end-user) were most attractive for investments in 2018? How these segments are expected to grow during the forecast period (2020-2025).4. Which manufacturer/vendor/players in the Data Management Platform Market was the market leader in 2019?5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.

Enquire for Discount in Report @www.readmarketresearch.com/check-discount/37406-world-antioxidant-supplement-market*Get Upto $1000 Flat Discount on All License Type.

About UsWe at Read offers wide range of business services including but not limited to Market Research, Syndicate and Custom Research, Company Research, Business Consulting, Audit & Risk, Communications, Finance, Information Technology, Legal & Compliance, Human Resources and Sales.

Contact:Read Market ResearchDev Dixit (Sales Manager)B-51 CMPDI, Korba, ChhattisgarhPhone: +1 646 583 1932Email:[emailprotected]Web:https://www.readmarketresearch.comFollow Us on:LinkedIN

Go here to read the rest:
Antioxidant Supplement Market 2026 Industry Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive, Regional, And Global...

Recommendation and review posted by Bethany Smith

Overview for Bilberry Extract Products Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics

The Bilberry Extract Products market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Bilberry Extract Products market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Bilberry Extract Products market. The report focuses on well-known providers in the global Bilberry Extract Products industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Bilberry Extract Products Industry will develop is also analyzed in detail in Chapter 1.7 of the report., In Chapter 2.4, we analyzed industry trends in the context of COVID-19., In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets., In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries., In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Bilberry Extract Products Market report @ https://www.arcognizance.com/enquiry-sample/1481413

Key players in the global Bilberry Extract Products market covered in Chapter 4:, Natrol Vitamins & Supplements, Nutraceutical, Nutrilite, Life Extension, Spring Valley, Kanbo Natural Health Food, Natures Way Products, LLC., Puritans Pride, Source Naturals, Inc., Biofinest, Now foods, Ahana Nutrition, GNC, Bluebonnet Nutrition, Swanson

In Chapter 11 and 13.3, on the basis of types, the Bilberry Extract Products market from 2015 to 2026 is primarily split into:, Tablets, Cheweables, Others

In Chapter 12 and 13.4, on the basis of applications, the Bilberry Extract Products market from 2015 to 2026 covers:, E-commerce, Medical Institutions, Supermarket

[emailprotected] https://www.arcognizance.com/discount/1481413

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

Years considered for this report:, Historical Years: 2015-2019, Base Year: 2019, Estimated Year: 2020, Forecast Period: 2020-2026

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Bilberry Extract Products Market

Chapter Four: Players Profiles

Chapter Five: Global Bilberry Extract Products Market Analysis by Regions

[emailprotected]https://www.arcognizance.com/purchase/1481413

Chapter Six: North America Bilberry Extract Products Market Analysis by Countries

Chapter Seven: Europe Bilberry Extract Products Market Analysis by Countries

Chapter Eight: Asia-Pacific Bilberry Extract Products Market Analysis by Countries

Chapter Nine: Middle East and Africa Bilberry Extract Products Market Analysis by Countries

Chapter Ten: South America Bilberry Extract Products Market Analysis by Countries

Chapter Eleven: Global Bilberry Extract Products Market Segment by Types

Chapter Twelve: Global Bilberry Extract Products Market Segment by Applications12.1 Global Bilberry Extract Products Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Bilberry Extract Products Sales and Market Share by Applications (2015-2020)12.1.2 Global Bilberry Extract Products Revenue and Market Share by Applications (2015-2020)12.2 E-commerce Sales, Revenue and Growth Rate (2015-2020)12.3 Medical Institutions Sales, Revenue and Growth Rate (2015-2020)12.4 Supermarket Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Bilberry Extract Products Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Bilberry Extract Products Market Size Growth Rate by Type (2020-2026)Figure Global Bilberry Extract Products Market Share by Type in 2019 & 2026Figure Tablets FeaturesFigure Cheweables FeaturesFigure Others FeaturesTable Global Bilberry Extract Products Market Size Growth by Application (2020-2026)Figure Global Bilberry Extract Products Market Share by Application in 2019 & 2026Figure E-commerce DescriptionFigure Medical Institutions DescriptionFigure Supermarket DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Bilberry Extract Products Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Bilberry Extract Products Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Bilberry Extract ProductsFigure Production Process of Bilberry Extract ProductsFigure Manufacturing Cost Structure of Bilberry Extract ProductsFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Natrol Vitamins & Supplements ProfileTable Natrol Vitamins & Supplements Production, Value, Price, Gross Margin 2015-2020Table Nutraceutical ProfileTable Nutraceutical Production, Value, Price, Gross Margin 2015-2020Table Nutrilite ProfileTable Nutrilite Production, Value, Price, Gross Margin 2015-2020Table Life Extension ProfileTable Life Extension Production, Value, Price, Gross Margin 2015-2020Table Spring Valley ProfileTable Spring Valley Production, Value, Price, Gross Margin 2015-2020Table Kanbo Natural Health Food ProfileTable Kanbo Natural Health Food Production, Value, Price, Gross Margin 2015-2020Table Natures Way Products, LLC. ProfileTable Natures Way Products, LLC. Production, Value, Price, Gross Margin 2015-2020Table Puritans Pride ProfileTable Puritans Pride Production, Value, Price, Gross Margin 2015-2020Table Source Naturals, Inc. ProfileTable Source Naturals, Inc. Production, Value, Price, Gross Margin 2015-2020Table Biofinest ProfileTable Biofinest Production, Value, Price, Gross Margin 2015-2020Table Now foods ProfileTable Now foods Production, Value, Price, Gross Margin 2015-2020Table Ahana Nutrition ProfileTable Ahana Nutrition Production, Value, Price, Gross Margin 2015-2020Table GNC ProfileTable GNC Production, Value, Price, Gross Margin 2015-2020Table Bluebonnet Nutrition ProfileTable Bluebonnet Nutrition Production, Value, Price, Gross Margin 2015-2020Table Swanson ProfileTable Swanson Production, Value, Price, Gross Margin 2015-2020Figure Global Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Global Bilberry Extract Products Revenue ($) and Growth (2015-2020)Table Global Bilberry Extract Products Sales by Regions (2015-2020)Table Global Bilberry Extract Products Sales Market Share by Regions (2015-2020)Table Global Bilberry Extract Products Revenue ($) by Regions (2015-2020)Table Global Bilberry Extract Products Revenue Market Share by Regions (2015-2020)Table Global Bilberry Extract Products Revenue Market Share by Regions in 2015Table Global Bilberry Extract Products Revenue Market Share by Regions in 2019Figure North America Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Europe Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Asia-Pacific Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Middle East and Africa Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure South America Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure North America Bilberry Extract Products Revenue ($) and Growth (2015-2020)Table North America Bilberry Extract Products Sales by Countries (2015-2020)Table North America Bilberry Extract Products Sales Market Share by Countries (2015-2020)Figure North America Bilberry Extract Products Sales Market Share by Countries in 2015Figure North America Bilberry Extract Products Sales Market Share by Countries in 2019Table North America Bilberry Extract Products Revenue ($) by Countries (2015-2020)Table North America Bilberry Extract Products Revenue Market Share by Countries (2015-2020)Figure North America Bilberry Extract Products Revenue Market Share by Countries in 2015Figure North America Bilberry Extract Products Revenue Market Share by Countries in 2019Figure United States Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Canada Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Mexico Bilberry Extract Products Sales and Growth (2015-2020)Figure Europe Bilberry Extract Products Revenue ($) Growth (2015-2020)Table Europe Bilberry Extract Products Sales by Countries (2015-2020)Table Europe Bilberry Extract Products Sales Market Share by Countries (2015-2020)Figure Europe Bilberry Extract Products Sales Market Share by Countries in 2015Figure Europe Bilberry Extract Products Sales Market Share by Countries in 2019Table Europe Bilberry Extract Products Revenue ($) by Countries (2015-2020)Table Europe Bilberry Extract Products Revenue Market Share by Countries (2015-2020)Figure Europe Bilberry Extract Products Revenue Market Share by Countries in 2015Figure Europe Bilberry Extract Products Revenue Market Share by Countries in 2019Figure Germany Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure UK Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure France Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Italy Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Spain Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Russia Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Asia-Pacific Bilberry Extract Products Revenue ($) and Growth (2015-2020)Table Asia-Pacific Bilberry Extract Products Sales by Countries (2015-2020)Table Asia-Pacific Bilberry Extract Products Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Bilberry Extract Products Sales Market Share by Countries in 2015Figure Asia-Pacific Bilberry Extract Products Sales Market Share by Countries in 2019Table Asia-Pacific Bilberry Extract Products Revenue ($) by Countries (2015-2020)Table Asia-Pacific Bilberry Extract Products Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Bilberry Extract Products Revenue Market Share by Countries in 2015Figure Asia-Pacific Bilberry Extract Products Revenue Market Share by Countries in 2019Figure China Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Japan Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure South Korea Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Australia Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure India Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Southeast Asia Bilberry Extract Products Sales and Growth Rate (2015-2020)Figure Middle East and Africa Bilberry Extract Products Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Bilberry Extract Products :

Read the original here:
Impact Of Covid 19 On Bilberry Extract Products Market 2020 Industry Challenges Business Overview And Forecast Research Study 2026 - TechnoWeekly

Recommendation and review posted by Bethany Smith

This week, the situation surrounding the review remained in doubt, with the Secretary of State for Defence Ben Wallace telling Parliament that the government was still assessing the implications of scrapping the multi-year spending review.

MPs and experts have expressed concern that only funding the Ministry of Defence (MOD) for a year would further postpone long-awaited spending decisions and add to a black hole in the departments modernisation budget.

Before the Covid-19 coronavirus pandemic struck, the UK had planned to publish the Integrated Review alongside a comprehensive spending review which would have set the MODs budget for four years, giving it room to make spending decisions.

On Monday, Wallace told MPs: The government announced on 21 October that they will conduct a one-year spending review for 2021-22. The implications of that decision for the integrated review are currently being considered. The government will provide an update to Parliament once this has been decided.

Labours Shadow Defence Minister John Healey criticised the confusion around the state of the review, saying: Is it not the regrettable truth that the Chancellor has cut the ground from under the Defence Secretary and our British forces? The Secretary of State rightly said that previous Tory defence reviews have failed because they were never in step with the spending plans.

They were a cover for cuts, which is why our armed forces are nearly 12,000 short of the strength promised in the 2015 review; essential equipment, from new tanks to the new radar system protecting our aircraft carrier, is long overdue; and the defence budget has a 13 billion black hole. A fully-fledged, fully funded strategic defence and security review is needed now more than ever. What does he say about the failure to deliver on that?

Wallace responded saying that no one has said yet that the integrated review will be delayed or curtailed but added that the government was studying the implications a one-year spending review would have.

Critical decisions on the future of the UKs Armed Forces are wrapped up in the Integrated Review, including the future of the British Armys main battle tank and infantry fighting vehicle (IFV) modernisation programmes. The army is in the final stages of negotiating contracts for the Warrior Capability Sustainment Programme (CSP) and Challenger 2 Life Extension Programme (LEP).

The British Army introduced Challenger 2 into service in 1998, and Warrior in 1984. Decisions on both upgrade programmes would likely have to be put off if the MOD only received a one-year budget.

MP and Chair of Parliaments Defence Select Committee Tobias Ellwood told Parliament that a one-year funding settlement would make the integrated review next to meaningless.

He added: The Prime Minister gave me a direct assurance that the integrated review would not be delayed. If global Britain is an instruction and not a strapline, this review is the road map to how we advance our defence posture to support our foreign policy ambitions.

Any delay to its publication with its full spending commitments will send a poor signal to the world that we are absolutely serious about re-establishing our global credentials and could prompt questions about our justification to retain a permanent seat on the UN Security Council.

The Prime Minister and the Defence Secretary have reportedly been pushing the Treasury to commit to a multi-year spending plan for defence.

In a paper published by the Royal United Services Institute (RUSI) titled A Reckoning Postponed? The Defence Arithmetic of the Integrated Review, the thinktanks deputy director-general Malcolm Chalmers wrote that the decision to abandon the multi-year spending review had thrown the Integrated Review into disarray.

Chalmers added that for defence, this decision would mean key decisions on long-term priorities would have to be pushed back to 2021 or 2022.

Chalmers added: A multi-year CSR, combined with a government committed to a radical foreign and defence policy review, would have provided the MoD with an important opportunity to get in front of these issues in relation to these two major programmes, as in other elements of the forward programme.

Now that the government has reverted to a one-year Spending Review, it will be harder to close on the key decisions that need to be taken. There is a risk that, despite the hard work that has gone into the 2020 Integrated Review, and the MDP before it, the MOD may have to repeat the exercise with a new Integrated Review (or at least a defence element of it) in summer 2021 or 2022. Such an outcome would not be good for defence, and it is likely to be bad value for money for the taxpayer.

CBRN Decontamination Equipment

Ground-based Air Defence Systems

Practice Grenades for Military Training

See original here:
Funding questions loom over the UK's Integrated Review - Army Technology

Recommendation and review posted by Bethany Smith

BROOKINGS What if damaged precast concrete bridge columns and building beams or columns could be replaced instead of having to demolish the structure?

That is the possibility a South Dakota State University graduate student and his adviser are looking at. Kallan Hart is a first-year graduate student from Faribault, Minnesota, who earned his bachelors in civil engineering in 2019. Mostafa Tazarv is an assistant professor in the Department of Civil and Environmental Engineering within the Jerome J. Lohr College of Engineering.

Work has just begun on the project, which is largely being funded by an award from the Precast/Prestressed Concrete Institute. Hart received the $40,000 Dennis Mertz Bridge Research Fellowship for 2020-21 and became the first SDSU student to receive an award from the institute. It is to cover his tuition, fees and living expenses as well as project costs.

Supplemental funds come from the National Center for Transportation Infrastructure Durability and Life Extension.

They will undertake a two-year study within the Lohr Structures Lab on campus in cooperation with industry partner Gage Brothers Concrete, Sioux Falls.

Tazarv explained steel bars are traditionally embedded within the columns or beams of a concrete structure. However, when a catastrophic event, such an earthquake, hits the structures, those bars often yield, and sometimes buckle or fracture. When the damage is extensive, the entire structure must be demolished, he explained. Hart and Tazarv will experiment placing the bars on the outside of the bridge columns, which are the main source of resistance against earthquakes and other extreme events.

Their theory is that those bars could be replaced while leaving the structure in place and saving millions of dollars as a result.

In initial testing in the Lohr Structures lab, Tazarv said the proposed repairable precast connections were investigated through cyclic testing of four half-scale beam-column specimens detailed based on a nine-story building designed for Los Angeles, which is a high seismic region. A reference cast-in-place beam-column specimen was also included for comparison.

The test results showed the repairable precast connections can withstand more than 14 times the design level earthquake with insignificant damage and ability to be repaired afterward.

Furthermore, Tazarv found precast buildings using the repairable technology can withstand extreme earthquakes with minimal damage and repair need. Now, it is the time to test the idea on bridges.

In the next two years, Hart will develop 10 new repairable details for bridge columns, rank them based on constructability, cost and expected performance, and test the top two repairable columns, each 10-feet tall, to failure.

Hart is excited to begin the research and be selected for the award.

Assisting on work in the lab the past few months has given me new insight into the seismic applications of structural engineering, despite residing in a low-seismic zone. Hopefully, our new detailing will provide transportation departments and other bridge owners an additional design option to reduce replacement costs in the inevitable event of an earthquake in high-seismic zones while also cutting the amount of time that bridges will have to be closed to the public, Hart said.

Tazarv called Hart a smart, outstanding and hardworking student. This fellowship will provide him an opportunity to perform an innovative research and also benefit from the industry partnership planned in the project.

Read the original post:
Brookings Register | Theory: Replaceable bars could save millions - Brookings Register

Recommendation and review posted by Bethany Smith

Introduction: Global Cryonics Technology Market, 2020-27

This in-depth research report presentation on Global Cryonics Technology market offers decisive market intelligence across multi-tier levels comprising regional, industry level, followed by further supply chain landscape.

The report is thoroughly structured to ensure ample understanding and information flow on new technological milestones, novel product expansion schemes as well as pipeline activities and investments likelihood besides regulatory developments that collectively influence a steady and robust growth trail in global Cryonics Technology market. Additional details such as consumer behavior, top stimulants as well as notable barriers that also tend to mold growth prognosis in global Cryonics Technology market.

Vendor LandscapeThe report draws references of an extensive analysis of the Cryonics Technology market, entailing crucial details about key market players, complete with a broad overview of expansion probability and expansion strategies.PraxairCellulisCryologicsCryothermKrioRusVWRThermo Fisher ScientificCustom Biogenic SystemsOregon CryonicsAlcor Life Extension FoundationOsiris CryonicsSigma-AldrichSouthern Cryonics

Available Sample Report in PDF Version along with Graphs and [emailprotected] https://www.orbismarketreports.com/sample-request/61891?utm_source=Puja

Unbiased research findings suggest an optimistic growth in global Cryonics Technology market securing a decent growth valuation and impressive CAGR percentage which is further anticipated to continue through the forecast span. These crucial report contents suggest that the aforementioned Cryonics Technology market is likely to overcome and emerge successfully from the pandemic constraints and echo favorable growth trajectory of the past decades.

Global Cryonics Technology Market: Type & Application based Analysis

Analysis by Type: This section of the report includes factual details pertaining to the most lucrative segment harnessing revenue maximization.Slow freezingVitrificationUltra-rapid

Analysis by Application: Further in the subsequent sections of the report, research analysts have rendered precise judgment regarding the various applications that the Cryonics Technology market mediates for superlative end-user benefits.Animal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

Reader Centric Queries: Global Cryonics Technology Market

The report showcases a detailed overview and scenario evaluation of the global Cryonics Technology market for the period, 2020-25

Accurate CAGR predictions through the forecast tenure, 2020-25

A clear understanding and analytical review of all the dominant factors that are likely to assist and ensure steady growth trail in global Cryonics Technology market during the next five years

Growth estimations in terms of value and volume-based growth across regions as well as global scenario

Read complete report along with TOC @ https://www.orbismarketreports.com/global-cryonics-technology-market-size-status-and-forecast-2019-2025?utm_source=Puja

COVID-19 Impact AnalysisThis intensively researched report presentation has been prepared in real time parlance, rendering substantial attention towards COVID-19 outbreak that has lately wreaked unprecedented damage across industries, stagnating growth.

The report lends attention towards evaluating the market in terms of exhaustive research in the times of COVID, as well as devising appropriate come back protocols to restore normalcy.

Decoding Regional Overview of the Cryonics Technology MarketApart from gauging into the present as well as future implications of COVID, the report is a dependable document to understand the dormant opportunities, new products and services that are likely to be more relevant in the post COVID-19 market. This section of the report therefore shares vital details and workable cues on new product profiles to help businesses revive from the COVID aftermath.

Report Deliverable: Global Cryonics Technology Market

This detailed and versatile report synopsis on global Cryonics Technology market has been prepared on the basis of thorough research studies, summation and synthesispractices after collating information from multiple sources. In essence, this Cryonics Technology market report presents data in the following categories:

Market size estimation at global and regional levels

Dominant and popular trends

A thorough analysis based on geographical expanse to identify top growth hotspots.

The report includes sections about growth probabilities that represent major disruptions.

In-depth research findings reflected in this report opine that despite the unprecedented outbreak and lingering implications of COVID-19 and its reformatory reforms reflected across industries, the immediate and future specific implications have been thoroughly classified and elaborated in the report to encourage unbiased market discretion.

Some Major TOC Points: Chapter 1. Report Overview Chapter 2. Global Growth Trends Chapter 3. Market Share by Key Players Chapter 4. Breakdown Data by Type and Application Chapter 5. Market by End Users/Application Chapter 6. COVID-19 Outbreak: Cryonics Technology Industry Impact Chapter 7. Opportunity Analysis in Covid-19 Crisis Chapter 9. Market Driving ForceAnd Many More

A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post COVID-19 market environment.

Shoot your queries at:@ https://www.orbismarketreports.com/enquiry-before-buying/61891?utm_source=Puja

Market Report Offerings in a Gist: A thorough reference of the dominant trends as well as relevant market dynamics Elaborate analysis and reference of core products and dynamic segments A thorough analysis of the competition spectrum and winning strategies of the major players COVID-19 analysis and recovery route PESTEL and SWOT analysis besides other analysis

The report has been conceived and presented in an attempt to decode notable business decisions and trends based on which a thorough evaluation spectrum has been constructed to encourage growth oriented business discretion amongst budding market participants as well as established vendors willing to ensure hassle-free growth stride despite challenges and rising competition.

About Us :

We are a team of highly professional researchers dedicated to unravel ongoing market developments. We are recognized as best in industry one stop store, offering intensively researched market-oriented information with superlative standards of impartiality and authenticity in order to rightfully influence favorable business decisions across a range of verticals. We are highly dependent on our information scavenging abilities and extremely reliant on our intuitive capabilities that lead towards novel opportunity mapping and result in profitable business models and high revenue structures.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

More here:
Global Cryonics Technology Market 2025 Current as Well as the Future Challenges: Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR - The Think...

Recommendation and review posted by Bethany Smith

Black Cumin Seed Oil (COVID-19 Version) Market 2020 Overview:

Reports Monitor has recently added a new report to its vast depository titled Global Black Cumin Seed Oil (COVID-19 Version) Market 2020. The report studies vital factors about theGlobal Black Cumin Seed Oil (COVID-19 Version) Marketthat are essential to be understood by existing as well as new market players. The report highlights the essential elements such as market share, profitability, production, sales, manufacturing, advertising, technological advancements, key market players, regional segmentation, and many more crucial aspects related to theGlobal Black Cumin Seed Oil (COVID-19 Version) Market.

Important factors like strategic developments, government regulations, market analysis, end users, target audience, distribution network, branding, product portfolio, market share, threats and barriers, growth drivers, latest trends in the industry are also mentioned.

TheTop Leading playersoperating in the market to Covered in this Report:Henry Lamotte OILS GmbH, FLAVEX Naturextrakte GmbH, Henry Lamotte Oils GmbH, Kerfoot Group, Earthoil Plantations, Life Extension, Nuverus, Omega Pharma, BioPraep& More.

Get PDFSample Reportof Black Cumin Seed Oil (COVID-19 Version) Market 2020, Click Here @https://www.reportsmonitor.com/request_sample/1044487

TheBlack Cumin Seed Oil (COVID-19 Version) Marketreport is segmented in the following categories:

Segmentation by product type :Food Grade, Cosmetic Grade

Segmentation by Application :Soap, Health Food, Personal Care Products (Massage Oils, Skin Care Products)

Following regions are highlighted in this report:

Understand the influence of COVID-19 on the Black Cumin Seed Oil (COVID-19 Version) Market with our analysts monitoring the situation across the globe.Get here sample analysis

The report on Global Black Cumin Seed Oil (COVID-19 Version) Market provides detailed segmentation by type, applications and regions. Each segment provides information about the production and manufacturing during the forecast period of 2015-2026. The application segment highlights the applications and operational processes of the industry. Understanding these segments will help identify the importance of the various factors aiding to the market growth.

The market research report on the Global Black Cumin Seed Oil (COVID-19 Version) market has been carefully curated after studying and observing various factors that determine the growth such as environmental, economic, social, technological and political status of the regions mentioned. Thorough analysis of the data regarding revenue, production, and manufacturers gives out a clear picture of the global scenario of the Black Cumin Seed Oil (COVID-19 Version) market. The data will also help key players and new entrants understand the potential of investments in the Global Black Cumin Seed Oil (COVID-19 Version) Market.

Avail discount while purchasing this report, Click [emailprotected]https://www.reportsmonitor.com/check_discount/1044487

Key features of this report are:

For More Details On this Report:https://www.reportsmonitor.com/report/1044487/Black-Cumin-Seed-Oil-Market

Contact UsJay MatthewsDirect: +1 513 549 5911 (U.S.)+44 203 318 2846 (U.K.)Email:[emailprotected]

Continued here:
Black Cumin Seed Oil (COVID-19 Version) Market Insights, Forecast to 2025 | Henry Lamotte OILS GmbH, FLAVEX Naturextrakte GmbH, Henry Lamotte Oils...

Recommendation and review posted by Bethany Smith

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18469

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are Avon Products Inc., Beiersdorf AG, Colgate-Palmolive Company, Kao Corporation, LOral S.A., Procter & Gamble, Shiseido Company, The Estee Lauder Companies Inc., Unilever PLC, Revlon, Clinique Laboratories, llc., Murad, LLC., SkinCeuticals, RMS Beauty, J.R. Watkins and 100% PURE.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/18469

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
The Medical Skin Care Products Market to witness non-linear transition from 2017 to 2025 - PRnews Leader

Recommendation and review posted by Bethany Smith

You most likely have noticed this phenomenon. When someone you know gets critically injured, experiences a serious illness or a major stressor, they soon look older. Sound familiar? Next time you see your friend, their hair is gray or even white. Have you ever wondered why that happens?

A new study from scientists at Harvard now reveals our sympathetic nervous system likely plays a major role in this process. The sympathetic nervous system is also called the fight or flight system. When youre in a stressful or dangerous situation, the sympathetic nervous system releases hormones to increase your alert level and heart rate to prepare you to act.

It all starts in a small area of the brain called the amygdala, and it eventually activates adrenal glands in the kidneys, which release adrenaline to coordinate the response of your internal organs and heighten your mental focus.

We have stem cells in the bottom of each hair follicle. These stem cells mature into cells called melanocytes, which produce pigment for our hair and skin color. Using mice, researchers found stressful events can lead to damage in the stem cells in our hair follicles.

Stress caused these stem cells to mature much faster than normal, which meant the supply of stem cells in the hair follicles eventually ran out. Without the stem cells producing melanocytes, the hair in the follicle lost its color and looked gray.

But how did this happen? The researchers thought maybe the immune system attacked these melanocytes resulting in the graying or that a hormone called cortisol produced by the adrenal glands might be responsible. Neither of those turned out to be the cause of the graying hair.

In some intricate experiments, the scientists discovered sympathetic nerve cells associated with hair follicles were the key. These nerve cells released a hormone called noradrenaline into the melanocyte stem cells, which caused them to mature and eventually disappear from the base of the follicle and caused the graying of the hair.

In other experiments, noradrenaline treatment of human melanocytes in lab cultures lead to rapid growth, suggesting this same process likely occurs in humans leading to the graying of hair.

Other scientists also have shown depleting melanocytes leads to a progression of the first gray hairs to gray and then to white fur in dark-colored mice, which sounds like what we see in humans.

So heres a question: If you have rapid growth of these melanocytes, can you prevent the hair from graying? The answer appears to be yes, based on the treatment of these same mice with drugs that block the release of noradrenaline.

This treatment couldnt be used in humans because blocking the flight or flight response would have severe consequences in other areas of our lives. But this new information could be used in the future for more specific drugs that would just work on the hair follicles. This would be a great benefit to me if I only had enough hair.

Medical Discovery News is hosted by professors Norbert Herzog at Quinnipiac University, and David Niesel of the University of Texas Medical Branch. Learn more at http://www.medicaldiscoverynews.com.

Original post:
Research providing better understand of graying hair | Health - Galveston County Daily News

Recommendation and review posted by Bethany Smith

David Shaw walks into the hospital room and takes a seat next to the bed. He does this nearly every day, right around lunchtime.

He looks at his younger brother, Eric, tubes snaking across his arms, machines beeping and whirring. Eric does not look like Eric anymore, his skin darkened, scars deepened, features altered. They both know this but never mention it.

Eric is dying, a rare, aggressive skin cancer rampaging through his body with such ferocity that his doctors are nearly out of options. Radiation failed. Chemotherapy failed. Two bone marrow transplants failed.

As Stanford's head football coach, David Shaw is relied on to always know what to say, how to say it and when to say it; but he cannot find the words now that he and his brother are staring down what seems to be an inevitable fate.

"What do you say, where you think you've pulled at the last thread and there are no more threads?" David said. "All I could tell him was that I loved him and that I was there for him. The rest of it was really just ... I thought it was only a matter of time before he passed away."

Two years later, what happened between David and Eric remains real, present and raw -- changing their entire relationship, redefining what it means to be a brother. The words are still difficult to say, so they tip-toe around the crushing physical and mental toll Eric's cancer took on them.

David and Eric are sure to think about it all this weekend, when Stanford opens its season at Oregon on Saturday. Because the last time the Cardinal visited Eugene, neither one knew whether Eric would live or die.

After Stanford came from behind to win that game 38-31 in overtime, David delivered a message at the end of his postgame television interview, looking at the camera and saying, "To my brotherEric: I love you." He tapped the lime green pin on his black Stanford sweatshirt before he left the screen.

When Shaw became head coach at Stanford in 2011, it was the culmination of a family journey. His father was a longtime coach there; David played receiver for the Cardinal and eventually returned as an assistant under Jim Harbaugh. The entire Shaw family -- parents Willie and Gay, along with David, Eric and their sister, Tawnya -- all call the Bay Area home.

To this day, David says the day he was introduced as coach was "one of the better days in all our lives."

Yet something started to happen to Eric that no one could quite figure out. That same year, Eric found strange looking spots on his torso. His wife, Crystal, noticed the first one under his arm. Maybe it was eczema, they thought. Then the spots started to spread. He went to the doctor. They prescribed an ointment, but the spots kept popping up, until they covered his entire body. Eventually, tumors started to grow. It looked as if someone had pushed marbles under his skin. Doctors remained confounded. Eric itched uncontrollably, insatiably. His skin itched so badly, it became difficult to put on clothes, shower, sleep and go to work. He eventually needed sleep medication so he could get uninterrupted rest.

Even then, he itched subconsciously, only realizing what happened when he woke up in the morning to find his arms and sheets covered in blood. Some nights, he tried to sleep on his forearms so his body wouldn't touch the sheets, because his skin grew too sensitive to any touch. At one point, he had more than 30 open wounds on his body.

"It's something that's so pervasive and so destructive that a lot of people have mental problems -- you can't do anything without extreme pain," Eric said. "You bleed a lot through the tumors, through the lesions, through the scratching. A lot of people don't survive, really, because of the mental stress that comes with it."

Doctors had a hard time diagnosing his disease because it is often confused with psoriasis, eczema or other skin conditions. Eventually, they determined he had a rare form of skin cancer called mycosis fungoides, a type of T-cell lymphoma that affects one in 6 million people in the United States and Europe. At the time, Eric Shaw was 38.

In 2013, he and Crystal pushed for a referral to Stanford Cancer Center, which has leading experts in the disease. Mycosis fungoides is so rare, it accounts for only 4% of all non-Hodgkin lymphoma cases; among those who suffer from it, only 20% have the type of itching Eric experienced. Rarer still is to find it in people under the age of 40, and African American men often end up with the worst prognosis. All the odds were firmly against him.

"When you first hear skin cancer, your mind doesn't go too far," David said. "So initially I was like, 'There are creams and other minor surgeries. I think it'll be OK.' And then Eric said, 'No, this is not the typical skin cancer. This is inside my body. This is inside the layers of my skin, and it's not one spot. It's everywhere.'

"I didn't really get it for weeks after that because, rectifying something that I didn't think was so serious to [then thinking] ... 'Oh my gosh. So this is really cancer. This is really scary now.' It took a long time for that to sink in."

David turned it over in his mind. He was the big brother, the protector, the one who always made sure Eric would be OK. They were supposed to raise their kids together, grow old together, and reminisce about the randomness of a life spent together.

He kept coming back to one thought: You're not supposed to lose your little brother.

David and Eric Shaw grew particularly close as children as they moved from place to place when their father, Willie, took new coaching jobs. Tawnya, their older sister, fit in anywhere socially. But David and Eric, who is two years younger, stuck together.

"Like a pair," David said.

They loved riding their bikes and, when they moved to Arizona, they took advantage of the wide-open spaces in the new development where they lived. They rode for miles and miles, setting up their own ramps and doing tricks and wheelies, visiting friends along the way before returning home after dark. They played sports, too, and though David loved football as much as their dad, the basketball court is where the brothers had their epic battles.

"I was always kind of a little bit stronger and I'll never forget the last time we played one-on-one basketball," David said. "He just got better than me, and he won, and once I got over the anger and disappointment, I was proud because my younger brother had grown and was gaining confidence."

Said Eric: "I wanted nothing more than to beat him, and he wanted nothing more than to keep beating me. But, during those times, it was just us, it was me and him. He was my best friend."

David went on to play at Stanford and eventually got into coaching, against his mother's best wishes. Eric did not pursue a career in athletics. He went to San Diego State and got into a career in marketing at a financial services company, where his gregarious nature, big smile and easy laugh made him a perfect fit. Though their personalities are different -- David is stoic and introspective, Eric makes anyone feel as if they have been friends forever -- they are grounded in the same values they learned at a young age: family and faith above everything else.

Those principles only grew stronger after they found themselves in the Bay Area as adults.

After David was hired by Stanford, the entire Shaw family made it clear it would always be around to support him. Family members all have a standing invitation to come for dinner on Tuesdays. And they always attend home football games, waving and hugging David during the team's pregame walk, cheering from the stands, and then waiting for some time together once the game ends.

Even as Eric grew sick, he made it a point to go cheer for his big brother. "It's not just the football game. Our family comes together," he said. "We celebrate, we come to watch the game and cheer the team on and support David. And then afterwards, win or lose, we all wait for him to come out. It's a family day. It's been wonderful to share that experience with David."

Stanford eventually drew them even closer, and it had nothing to do with football.

Eric did not understand the gravity of his situation until his first meeting in 2013 with the doctors at Stanford Cancer Center. They put it bluntly: He had such an aggressive form of the disease that he needed immediate treatment. They would start with total skin radiation, preparing Eric to lose his hair, eyebrows, eyelashes, fingernails and toenails.

If that did not work, they would try chemotherapy next.

"All these thoughts are running through your mind," Crystal said. "'Is he going to make it? Is it going to work? What's going to happen?' At the time, our youngest daughter was 3 months old, so it was pretty overwhelming. We were just putting our lives together and then boom: you're in the middle of this cancer war."

The next week, Eric took a leave of absence from work and began four-times-a-week trips from their home east of Palo Alto, California, to Stanford Hospital, often driving as many as three hours one way in traffic. When he arrived, he went into a box and his whole body was exposed to the radiation light for about an hour. Then, he would make the drive back home to see Crystal and their four kids -- Caleb Michael, Jared Spann-Shaw, Madison Shaw and Olivia Shaw.

The radiation charred his skin. He lost weight. When he looked in the mirror, Eric no longer recognized the man looking back at him.

"Nothing prepares you for something like this," he said. "Knowing that other people were looking at me and knowing that something was very wrong, that was a daily grind to get myself up out of bed and get ready for the day, knowing that that was going to be my life."

He did this for three straight months, all to keep the disease from growing to a point where it would kill him. It worked for a short time, but the disease came back more aggressively six months later. Doctors moved on to chemotherapy treatments, some of them experimental, but also began discussing the last-resort option: a bone marrow transplant.

David and Tawnya immediately volunteered to become donors, and underwent testing. In most cases, siblings are the best chance at a donor match. Unfortunately, in their case, neither was close. On a 10-point match scale, Tawnya registered a 3, David a 5. Neither qualified to donate.

"I wanted to jump to the front of the line and say, 'Whatever I have to do, whatever you have to take out of me, however you have to do it, just do it,'" David said. "For them to come back and say that you're not a strong enough match was disheartening. It hurt me. The fact that we had to put our trust and faith in people that we didn't know, and that we're going to have to go out to registries and try to find someone who was a better match than I was, that uncertainty, and that doubt, it's hard to keep it at bay at that point. It starts to creep in."

Doctors eventually found two donors whom they believed could work, but they were not perfect matches. In early 2018, Eric and his family moved into a two-bedroom apartment near Stanford Hospital to prepare for the transplant. For three months, he went through radiation, then chemotherapy to prepare his body to accept the donor cells.

He underwent the transplant in April, feeling confident and inspired it would work. After a month, doctors did an initial check to see how many of the donor cells had survived the transplant.

None survived.

"It was like I never even had the transplant," Eric said. "That was so devastating. We just knew it was going to work. I mean, we're people of faith, and we knew everybody was praying for us, and that we were praying that this six-year journey was going to finally be over. And it wasn't over. It was crushing for them to say, 'It didn't work. We're going to have to try again.'"

The second attempt happened in September. Crystal bought lime green pins for the family to wear for lymphoma awareness. Without telling Eric or Crystal, David decided he would wear his on his shirt for the 2018 football season. In addition to that, he had lime green and yellow ribbons placed on the back of Stanford helmets as a way to show support for both cancer patients and cancer survivors.

He told his team that his brother was fighting cancer, and briefly mentioned the helmet ribbons publicly during an early-season news conference. But beyond that, David kept the severity of what was happening to his brother to himself, masking his growing nervousness, fear and anxiety as the clock ticked toward the next transplant. He had a hard time processing what was happening. He did not want to put that at the feet of his players, or his staff.

The doctors used the same donor cells that failed the first time for the second transplant on Sept. 11, 2018, because that was the only option available. But this time, doctors used even stronger drugs to prepare Eric's body to receive the donor cells -- hoping that would do enough to stop his immune system from attacking them.

When Stanford played Oregon on Sept. 22, no one in the Shaw family knew whether the transplant had worked. But the situation was more dire than the first transplant. The stronger chemotherapy caused major complications, and Eric became severely ill.

David coached the game with this in the back of his mind. Stanford rallied from a 21-7 deficit to win an overtime thriller, moving to 4-0 on the season, with a top-10 matchup against Notre Dame the following week. Back in Palo Alto, Eric watched the entire game alone in an apartment he rented near the hospital, the comeback buoying his spirits.

He had no idea his brother would speak to him through the television until he heard the words, "To my brother Eric ..."

"In that moment, I didn't feel any sickness at all," Eric said. "I can't really describe what I felt, just how proud I am of him and how awesome it made me feel that he would do that for me."

Said David: "If that transplant didn't work, I didn't know how many more games he was going to be able to see. That was an opportunity for me on national TV to speak to him, to say to my brother that against the odds, we came back and throughout the entire game, I was thinking about him."

Eric soon returned to Stanford Hospital. The chemotherapy destroyed his blood system, so he needed daily blood transfusions to stay alive. It came as no surprise when doctors told him the second transplant had failed. They had no plan now, no other donor options. David came by to visit as often as he could, but he had a hard time finding the words to say to his dying brother.

"I thought about Crystal. I thought about their kids," Shaw said. "I thought about, 'How can we help?' And then I kept going, 'We just can't get there. There has to be something else.' And we all prayed and we all comforted each other and trusted the doctors and prayed for the doctors. And just kept saying, 'Just tell us whatever options there are. Just tell us what to do and we'll do it.'"

During the day, Eric had his mother, Crystal, David, or David's wife, Kori, at his side, helping to keep his mind off what was happening to him. But in the evenings, when he was alone in his hospital room, he couldn't help but think about the dwindling medical options and his own death, slowly accepting what he believed would inevitably come.

Over seven years, everything the doctors tried had failed, and the disease always came back more aggressively. He felt exhausted in every possible way, desperate to feel better. He didn't want to die. All he wanted to do was get better, and see his kids again, hug his wife and go home. But that possibility seemed as far off as the stars.

"The doctors couldn't help us," Eric said. "They had lost all hope. There was nothing left, but we were in the deepest part of the valley, and there was nobody there but God. I said, 'You're going to take me off this Earth.' And he told me, 'Eric, you're not going to die.' That was the point at which my faith really took over, and I really had true peace."

His team of doctors huddled together again and came up with a plan many of their colleagues questioned, simply because they had never attempted it. In mid-October of 2018, they told Eric they wanted to try a third transplant.

Only this time, they wanted David to be the donor and they had only weeks to make it happen.

Eric thought, "Are they trying to kill me?"

When David was initially rejected, doctors had worked for 25 years to find a way to do half-match transplants but had virtually no success. By 2018, doctors explained that a different way to do the transplant had emerged, opening up the potential to try it with Eric. These transplants, called haploidentical transplants, typically use donor cells from a family member.

Dr. Wen-Kai Weng, Eric's bone marrow transplant physician, explained, "It was relatively new at this time. We decided to go ahead, because we knew if we didn't do it, the disease would really come back with a vengeance."

No one had ever done a third transplant with donor cells at Stanford.

"If he didn't go for this risk, he wouldn't be here," said Dr. Youn Kim, who treated Eric and heads Stanford's multidisciplinary Cutaneous Lymphoma Clinic/Program. "He wouldn't be living."

Doctors told Shaw there was a 15% chance he would not survive the transplant itself. If he did survive it, there was only about a 30% to 40% chance the donor cells would work. Compared to much steeper survival odds with no transplant at all, the decision -- filled with multiple layers of danger -- did not feel risky at all.

They had to try.

"They might have told us what the odds were, and I honestly just pushed it out of my brain," David said. "If this is the Hail Mary, hey, we're going to drop back and throw it as far as we can and send prayers along with it and hope that it works."

Without hesitation, David said to his brother, "Tell me what I need to do."

Stanford gathered in its team hotel early on Oct. 27 to begin final preparations before hosting Washington State later that day. David checked in for a 9 a.m. meeting and when it finished, he checked out of the hotel without saying a word. He walked toward the back exit, careful to make sure no one saw him, and snuck out the door to a waiting car.

Shaw sat in the passenger seat, headed toward campus and Stanford Hospital, praying all the while that what he was about to do would work.

He arrived at the hospital and was hooked up to an IV for the first dose of medication. This would not be the more traditional bone marrow transplant, where cells are extracted with a needle through the hips. Rather, the medication flowing through the IV would stimulate his body to overproduce the stem cells needed for the transplant, flooding his blood with them. The cells would then be extracted from his blood, and transplanted into Eric.

Doctors told him to expect to start feeling joint pain and tiredness within 24 hours. Those symptoms would grow only stronger over the coming days, when he came in for more medication. They told him he should stay off his feet, rest and remain hydrated.

That would be nice, David thought. But he had a game to coach. Only two people inside the program knew he had gone that morning: assistant athletic director for football operations Callie Dale, who drove him to the hospital, and defensive coordinator Lance Anderson.

"The way that I do my job, I work really hard not to make it about me," David said. "Although I wanted my team to know what my family was going through, college football is about the student-athletes. I wanted them to focus on what they needed to do. I didn't want to pull from that. I didn't want to, all of a sudden, now make it about me and my family."

A few hours later, he returned to the team hotel and acted as if he had been there the entire day, speaking nothing about his trip to the hospital. Shaw put on his lime green pin and made his way toward the bus. The short ride to the stadium felt long that day. His mind wandered before returning to the flip card in front of him.

As he exited the bus and finished the walk to the stadium, his two young nieces ran up to him. They squeezed him, holding on longer than usual, as if they knew their Uncle David was their only option, too.

He worried players would notice him moving around so slowly. If they did, no one said a word. Shaw kept pushing the pain aside, shoving his emotions down deep, saying prayers every chance he got.

On Wednesday, Shaw woke up and was so lethargic, he felt as if he was moving like a sloth. He went to the hospital for the final procedure: extracting the cells from his blood. Shaw wore comfortable clothes, arranged his pillows and settled in for a long day ahead. Doctors hooked him up to a machine that would do the work through two IVs: One took his blood so the needed donor cells could be siphoned out; the other IV would put the blood back in his body.

Eric rested on another floor in the same hospital.

David worked on his game plan, watched a few movies and occasionally stared at his own blood in the IVs, willing it to save his brother. He kept saying to himself over and over again, "God, I hope this works."

After eight hours, he was finished. Shaw then went out to practice.

"I remember walking up to him and just asking him, 'How are you doing, how are you feeling?'" Anderson said. "I could see it in him that he wasn't his normal self. He paused for a little bit and then he's like, 'I'm OK. A little bit tired, but I'm OK.' You know, just trying to put the most positive light that he could on it."

The next day, Nov. 1, 2018, Shaw went back to the hospital. It was transplant day, and he had to be with Eric to witness what they hoped would be a miracle. David and Crystal watched as Eric received a transfusion of David's stem cells, a shimmering light pink fluid flowing into his body. They sang and prayed. Already, they had received one small bit of good news: Doctors extracted 28 million cells from David's blood, about 20 million more than what they had hoped to get.

Stanford traveled the following day to Seattle, for a game against Washington. David felt guilty for leaving, but he knew there was nothing else he could do. Eric struggled in the hospital, not only from the transplant, but from the heavy chemo and radiation doctors used to prepare his body for the new cells.

Eric ran a fever of 105 degrees and vomited for days. The pain grew so intense he was put on a morphine drip and was in and out of consciousness. In Seattle, Shaw remembers being locked into the game, "except for those little moments where my heart was with my brother."

Stanford lost another heartbreaker, 27-23.

"I know us losing had nothing to do with everything David was going through," Dale said. "But just piling that on with everything else he was dealing with, it was a lot for him. He brought that up many times, about how Eric would tell him the biggest excitement for him every week was watching us play and watching us win. I know David had a lot of pressure on himself, amongst the pressure he already has as a head coach, to win for Eric. And I know that every time he did, he really felt like it was for him. And when we came up short, I know he was probably even harder on himself than he normally would have been."

Back at Stanford, David visited Eric when he could. But the waiting game took an increasing mental toll. David prides himself on his ability to compartmentalize, to focus on the only thing in front of him. He never spaces out, and he rarely gets emotional. But Shaw was falling apart on the inside.

He often found himself staring at cut-ups of red zone plays, not realizing the film had been paused for 20 minutes while his mind drifted off. Whenever that happened, he would stop and call someone, either his brother, his wife, his mother or Crystal just to see how they were doing.

"There were times where I thought life was slow motion, but it was actually moving and I was the one who was in slow motion," David said. "I found myself sometimes saying, 'Is this real? Is this really happening? This shouldn't happen.'"

In the middle of every single meeting, in the middle of every single film session, he silently prayed, "God help my brother. Just please let this one work."

"I look back now and I know more of everything that was going on and the situation," Anderson said. "I realized how much he was dealing with and how much he had to bear that week. And it's amazing that he was able to go through that week without really letting any of us really know exactly what he was going through and what a big deal this really was."

Within a few weeks, Eric started to turn a corner. Though they did not know whether the transplant had worked just yet, he showed enough improvement to leave the hospital after 52 days. David arrived for the big day, and Eric slowly put on a protective mask before shuffling to a waiting wheelchair. Doctors, nurses and support staff lined the hallway, clapping and cheering.

David cries when recalling that moment, his pent-up emotions flooding out as he describes it publicly for the first time.

"This is my little brother, after years of cancer, getting to leave the hospital," Shaw said, his voice quavering. He pauses to wipe tears from his eyes. "The nurses were crying. The doctors were crying. Because a few months earlier, they were preparing us for him to die. And he got to go home."

Three days later, doctors met with Eric and Crystal to deliver the results from the transplant. After only 27 days, Eric had none of his own blood coursing through his body.

It was all David's.

Eric picked up the phone.

"Dave," Eric said. "You have a twin. We're truly blood brothers."

Eric, who turns 46 on Friday, has lived a fairly normal life since he was declared cancer free on Jan. 1, 2019, although the coronavirus pandemic has limited how often the Shaw family can see each other.

In September, they decided to get together to celebrate all of their recent birthdays at David's house. They stayed outdoors, socially distanced, with masks on. Eric and David allowed themselves a hug, their heads turned to the side.

"Every time I see him, I just smile, you know? Because he gets to be here," David said.

See more here:
'We're truly blood brothers': Stanford coach David Shaw and his recent fight to save his brother, Eric - KGO-TV

Recommendation and review posted by Bethany Smith

The latest research report on the Anti-Ageing Drugs Market Industry Analysis, Market Size, Opportunities and Forecast, 2020 2028 provides a comprehensive assessment of the Anti-Ageing Drugs market for the forecast period from 2020 to 2028, including market values for the years 2018 and 2019. The investigative report provides a detailed analysis of the impact of COVID-19 on various segments in the Anti-Ageing Drugs market based on product type, application, and end-use across numerous countries around the world. Further, the report also provides insights into market developments, trends, supply and demand changes across various regions across the globe. Thereby, the report provides a holistic view on the Anti-Ageing Drugs Market in order to help decision makers with various strategic insights and future outlook. The Anti-Ageing Drugs market is expected to witness continued growth during the forecast period from 2020 to 2028.

Leading companies reviewed in the Anti-Ageing Drugs Market report are: La Roche-Posay, Revision Optics, Calico, Nu Skin, LORAL, Unity Biotechnology

Get Free Exclusive Sample of this Premium Report at: https://www.zealinsider.com/report/6400/anti-ageing-drugs-market#sample

The report covers various aspects of the Anti-Ageing Drugs market segmented into product type, application and end-use. The report provides market numbers for the years 2018 and 2019 based on actual market findings also market estimates for forecasts for the period from 2020 to 2020 for each of the products types, applications and end-use segments.

Furthermore, the report includes a detailed competitive analysis among the market participants in the Anti-Ageing Drugs market. The report offers an in-depth comparative analysis of the competitors in the market based on their product offerings, market share and geographic presence. Some of the leading companies covered in the report include La Roche-Posay, Revision Optics, Calico, Nu Skin, LORAL, Unity Biotechnology

***NOTE***

We are continuously monitoring the market developments and changes occurring as a direct or indirect impact of the ongoing COVID-19 pandemic. Thereby, we are in a position to provide information on the market values and trends for both pre-COVID-19 and post-COVID-19 scenarios.

Target audiences for the report include:

Anti-Ageing Drugs Market Segmentation, By Product Type:Serums and supplements, Antioxidants and enzymes, Stem cells and drugs

Anti-Ageing Drugs Market Segmentation, By Application:Skin and hair, Skeletal and muscles, Age-related disorders, Others

Anti-Ageing Drugs Market Segmentation, By Geography:

Access Full Report information, here: https://www.zealinsider.com/report/6400/anti-ageing-drugs-market

Key Focus Areas in the Report:

View post:
Global Anti-Ageing Drugs Market (2020) to Witness Huge Growth by 2026 | La Roche-Posay, Revision Optics, Calico, Nu Skin, L'ORAL, Unity Biotechnology,...

Recommendation and review posted by Bethany Smith

Products featured are independently selected by our editorial team and we may earn a commission from purchases made from our links; the retailer may also receive certain auditable data for accounting purposes.

It makes sense to look to celebrities for beauty advice after all, theyve logged a lifetime of sitting in hair and makeup chairs. Musicians are also cashing in on what theyve learned from the pros, and launching lucrative cosmetics, skincare, and hair care lines in their own names.

The latest among the entrepreneurial pop star set to debut a beauty brand is Jennifer Lopez, who earlier this summer teased her forthcoming JLo Beauty label on Instagram, joining an empire that already encompasses fragrances and fashion. A trademark request that Lopez filed in 2019 reveals that the line will include skin moisturizers, skin cleansers, beauty masks, non-medicated skin serums, and face and body creams.

Lopez has yet to reveal JLo Beautys drop date, but the multi-hyphenate entertainer recently unveiled a hair care collection with womens wellness brand Hers (more on that below).

The best celebrity beauty brands give fans a chance to get a piece of their favorite singers off-stage, while supporting their non-musical entrepreneurial endeavors.

Check out some of our favorite celebrity beauty brands helmed by chart-topping artists, including Kesha, Lady Gaga, Madonna, Rihanna, Selena Gomez, and even David Lee Roth (that is not a typo). Heres what to shop from the best celeb brands online.

Launched in 2019 on Amazon Prime Day, Lady Gagas Haus of Laboratories beauty line is comprised of gender-neutral cosmetics for transforming into Mother Monster-approved looks. The vegan and cruelty-free collection features show-stopping eyeshadow palettes in glittering shades, vibrant lip colors, liquid eyeliners, and more, all created to inspire self-expression and invention, per a release.

Amazon

Rihannas Fenty Beauty was a smashing success when it debuted in 2017, thanks to its inclusive range of cosmetics available in over 50 shades. The makeup line features lightweight formulas and includes products for eyes, lips, face, and body, including foundations, powders, liquid eyeliners, lipsticks, bronzers, and much more, plus beauty tools and brushes. The brands convenient online shade finder also makes it easy to match your skin tone.

Sephora

Cruelty-free Fenty Skin is the latest addition to the superstar-turned-entrepreneurs lifestyle empire, joining LVMH-owned sister brands Fenty Beauty and the lingerie line, Savage X Fenty (coming soon is RiRis luxury fashion house, Fenty.) The gender-inclusive clean skincare label launched earlier this year with multi-tasking and refillable products that work effortlessly together, including a cleanser, toner serum, and SPF 30 moisturizer.

New to the lineup is the Instant Reset cream, an overnight gel that promises to reduce fine lines, wrinkles, and dark spots and decrease the size of pores. The brand is available exclusively on FentySkin.com.

Fenty Skin

Following the release of her album,Rare, in January,Selena Gomez dropped her much-anticipated makeup line, Rare Beauty, at Sephora in September. The products come in stylish packaging and everything is under $30, including lightweight and breathable foundations (which come in nearly 50 shades), blush, concealers, powders, lipsticks, eyeshadow palettes, beauty tools, and more cosmetics in inclusive colors.

Sephora

Set to ship in mid-November, J. Los first collection with womens wellness company Hers includes two new hair care products formulated without parabens, phthalates, and sulfates. The artist helped develop the California coast-scented Rapid Repair Hair Mask, which features keratin and hydrating ingredients to repair damaged strands; and the soothing Detox Scalp Scrub, which is made with sugar scrub, aloe extract, and salicylic acid for breaking down product buildup, oil, and dead skin.

Hers

MAC Cosmetics continues its tradition of teaming with musical artists in its latest collaboration with Grammy-winning Spanish singer Rosala. The newly-appointed brand ambassadors limited edition VIVA GLAM 26 lipstick was inspired by her iconic red looks and signature Spanish style, and all proceeds will benefit the MAC VIVA GLAM fund, which supports HIV/AIDS and LGBTQ+ communities as well as female empowerment initiatives.

MAC

Kesha teamed with cruelty-free and clean cosmetics brand Hipdot on a collection thats about embracing who you are [and] expressing yourself while we stand fearlessly together to celebrate our differences. Priced from $26 to $36, the line was inspired by intergalactic hues and features a 12-shade eyeshadow palette, a lipstick and gloss duo, and two-sided liquid eyeliner. (Collectors sets have since sold out.)

Hip Dot

Van Halen frontman (and former part-time EMT) David Lee Roth teamed with business partner and Tattoodo co-founder Ami James for Ink, a line of tattoo-focused skin care products. The brand is comprised of fragrance- and cruelty-free balms, moisturizers, and SPF 50 sunscreens, all formulated to keep ink looking as new as the day you got it. Theyre also made without parabens, artificial dyes, petroleum, and mineral oil.

Amazon

After debuting in Asia in 2014, Madges luxury skincare line, MDNA, arrived in the U.S. in 2019. The company (which shares a name with the OG pop queens 2012 album) uses Japans innovative techniques and miraculous thermal water sourced from Montecatini, Italy. Think best-sellers including the multi-tasking Reinvention Cream thats packed with plant stem cells for bringing visible radiance back to the visage, and restorative eye masks that de-puff and soothe. The Madonna-owned brands face and body-contouring Beauty Roller is also quite the hit.

MDNA Skin

Visit link:
From Tattoo Balms to Bronzer, Heres What to Buy From the Best Musician-Backed Beauty Brands - Rolling Stone

Recommendation and review posted by Bethany Smith

Facial hair, like scalp hair, grows in stages and understanding it may help you maximize your beard-growing potential.

A full beard can take 2 to 4 months to grow, as facial hair tends to grow between 0.3 and 0.5 millimeters (mm) every 24 hours. This works out to between one third and one half an inch per month.

Many factors can affect the growth of your beard, but there are some lifestyle strategies you can try to enhance your beard growth. Read on to learn more about what influences beard growth and if it can be influenced.

Once you stop shaving, you can expect facial hair to grow in stages. Hair may grow fuller and faster in certain areas, especially at first. Be patient, though, as this is a normal growth pattern for most guys.

Your ethnicity, age, genetics, and hormones not to mention various medical conditions can all affect whether your beard comes in faster or slower, or in all the places you desire.

If your beard seems to be taking a long time to grow in, one of the following factors may be at play.

You may remember guys in high school who seemed to have a full beard before they got their drivers license. Theyre the exception, not the rule.

Typically, full beard growth is possible starting at around age 18, but for many men, that time may not arrive until theyre 30. So, if youre not getting the beard growth you want, it may be because its not your time.

Certain ethnic groups tend to be more hirsute than others. Chinese men, for example, generally have less facial hair than white men, and men of Mediterranean descent generally have thicker beards.

Beyond your ethnic origins, your direct family traits have much to do with whether you can grow a full beard. Likewise, your genetics also determine the texture of your hair, your likelihood of going bald, and so forth.

For clues about your beards future, look to your male relatives. While theres no guarantee that a dad with a full beard will have a son who can pull off the same thing, hair patterns do tend to be hereditary.

Low levels of testosterone can make it more difficult to grow a beard. Talk with your doctor about taking supplements or trying testosterone therapy to help combat low testosterone.

If you want to grow your beard faster, there are a few strategies worth trying. Understand, however, that these tips may not work for everyone.

For general health, its recommended you have a balanced diet that includes fruits, vegetables, whole grains, and lean proteins, while avoiding processed food and added sugars.

For healthy hair growth, some key nutrients should have a place in your diet, including:

Too much stress and too little sleep can cause countless health problems, not to mention affect your beard growth.

Aim for 7 to 8 hours of sleep each night, and try strategies such as meditation or deep-breathing techniques to help de-stress.

Its not uncommon for guys to have thicker hair around their mouths and parts of their sideburns but a little less on their cheeks.

One way to help mask thinner (or zero) growth in those spots is to let the hair around them grow longer. You can hide those sparse spots a little with longer beard hair nearby.

Hair growth, whether its on your scalp or your face, is subject to many changes in your health.

Underlying medical conditions such as alopecia barbae or alopecia areata can cause hair loss from your beard or make it harder to grow a beard that isnt patchy or thin in places.

Alopecia areata is the more common condition. It occurs when the bodys immune system mistakenly attacks healthy hair follicles. When beard alopecia areata develops, men are usually middle-aged and hair loss is typically along the jawline.

Unusual conditions, such as prolactinoma a noncancerous tumor of the pituitary gland can also result in thin or missing facial hair.

Conversely, a noncancerous birthmark called Beckers nevus can sometimes cause excessive, coarse hair to form at the site of the birthmark.

The time it takes to grow a beard not to mention the look of the final product varies from person to person.

If youre trying to grow a full beard, plan on waiting a couple of months before you reach your goal. That means being patient and watching for signs of medical conditions that may affect your beard growth.

If youre concerned about a lack of beard growth, talk with your doctor or a dermatologist.

See the original post here:
How Long Does It Take to Grow a Beard? Tips, Genetics, and More - Healthline

Recommendation and review posted by Bethany Smith

The latestrelease from Database of WM Research, The Global Male Breast Cancer Market opportunities and current market scenario, providing insights and updates about the corresponding segments like Male Breast Cancers MarketSize, Share, Growth, Manufacturers, Regions, Type, and Application, Forecast to 2027.The report provides detailed assessment of key market dynamics and comprehensive information about the structure of theMale Breast Cancer industry. This market study contains exclusive insights into how the globalMale Breast Cancer market is predicted to grow during the forecast period.

In addition, the statistical research for the Male Breast Cancer Report focuses onproduct specifications, costs, capacity, marketing channels, and market players.Upstream raw materials, downstream demand analysis, and end-user industry listings have been systematically studied with vendors in this market. Product flows and distribution channels were also presented in this research report.

Download the Free Sample Copy of this Report:https://www.worldwidemarketreports.com/sample/366540

The outbreak of the pandemicCOVID-19changed the market scenario on the global platform. Many of the regions are facing the biggest economic crisis owing to the lockdowns that were implemented due to the outspread of the coronavirus infection. As the only solution that has been found to contracting this disease is social distancing many countries have implemented strong regulations in regards with people gatherings. Owing to this many of the businesses are working with only 30% of its employees thus not able to bring the maximum production.

Thiscan affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the FREECovid-19 Impact Analysis + Industry Updates on Male Breast Cancer Report:https://www.worldwidemarketreports.com/covidimpact/366540

Market Attributes

Details

Market size value in 2020

USDXX Million

Revenue forecast in 2027

USDXX Million

Growth Rate

CAGR of XX % from 2020 to 2027

Base year for estimation

2019

Historical data

2016 2019

Forecast period

2020 2027

Report coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends

Country scope

U.S., Canada, Mexico, U.K., Germany, France, Italy, China, India, Japan, Brazil, Argentina, Saudi Arabia, South Africa

Key companies profiled

Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare Customization Available

Medication, Chemotherapy, Others

Section 1: Market Introduction

This section deals with the Male Breast Cancer market definition or the market along with the target audience of the market. Later in the chapters, the research methodologies and the market tools that were used for the market analysis is mentioned.

Section 2: Male Breast Cancer Market DROC

The flow of this section is: Male Breast Cancer market growth factors and limitations. In the later chapters, the Male Breast Cancer market opportunities and challenges are described. All the points mentioned within the report are updated based on the COVID-19 situation.

Section 3: Conclusion and Observations

Last section of the report includes comments and observations by the research analysts and the market experts for the Male Breast Cancer market.

Do you have any Query or any customization with this report, please get in touch with our business experts at:https://www.worldwidemarketreports.com/quiry/366540

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: sales@worldwidemarketreports.com

View original post here:
Strategic and COVID-19 Analysis of Male Breast Cancer Market with Profiles like- Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis - re:Jerusalem

Recommendation and review posted by Bethany Smith

The Global Male Breast Cancer Treatment market research report comprises the description of allmajor aspects concerning the Male Breast Cancer Treatment market. It provides thehelpful information that focuses on the key aspects and features linked to the market current and forecast growth trends, and clarify it with the help of appropriate statistics. The global market research report also includes the in-depth information regarding the leading market. Competing with one another as well as developing industries in terms of value, the volume of sales, demand, and quality of products and services.

The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Male Breast Cancer Treatmentindustry. Growth of the overall Male Breast Cancer Treatmentmarket has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Request For Exclusive Sample PDF along with few company profileshttps://www.worldwidemarketreports.com/sample/366541

Impact of COVID-19:

Male Breast Cancer Treatment Market report analyses the impact of Coronavirus (COVID-19) on the Male Breast Cancer Treatment industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Male Breast Cancer Treatment market in 2020.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies.https://www.worldwidemarketreports.com/covidimpact/366541

The major players profiled in this report include

Market Segments and Sub-segments Covered in the Report are as per below:

Based on Product TypeMale Breast Cancer Treatmentmarket is segmented into

Based on ApplicationMale Breast Cancer Treatmentmarket is segmented into

Regional Coverage of theMale Breast Cancer TreatmentMarket:

PurchaseMale Breast Cancer TreatmentMarket Research Report @https://www.worldwidemarketreports.com/buy/366541

Key Questions answered in the Report:

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players Listhttps://www.worldwidemarketreports.com/discount/366541

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read the original post:
Male Breast Cancer Treatment Market Analysis -Worldwide Opportunities, Revenue, Production, Demand and Geographical Forecast To 2027 - Eurowire

Recommendation and review posted by Bethany Smith

Science has enabled physicians to predict the likelihood of a woman getting breast cancer, much in the same way that meteorologists determine where and when a tornado will touch down and Amazon ensures you receive your order quickly. Predictive modeling, when coupled with powerful tools such as genetic testing, helps doctors prevent breast cancer or detect it early when it is most curable.

Miami Cancer Institutephysicians are at the forefront of these data-driven advances, working to prevent cancer as much as they are focused on curing it. Recently the Institute opened theBreast Cancer Prevention Clinicspecifically for those with a genetic predisposition to breast cancer or another underlying issue that makes them more susceptible. This concept ofprevivorship promotes fighting breast cancer before ever getting it.

In this clinic we will tailor a prevention plan for these patients, saidJane Mendez, M.D., chief of breast surgery at Miami Cancer Institute, so that instead of becoming a breast cancer survivor, they can continue as aprevivor. Meaning that even though you have the increased predisposition to breast cancer, we keep it at that.

With Breast Cancer Awareness Month in October, Dr. Mendez, sat down with Jonathan Fialkow, M.D., deputy medical director and chief of cardiology at Miami Cardiac & Vascular Institute, for a recent episode of theBaptist HealthTalk podcast, Breast Cancer: Risks, Prevention and Previvors. They discussed the latest breast cancer advances, as well as the basics such as screening guidelines and prevention recommendations.

Below are edited excerpts from their conversation. You can also access this and other Baptist HealthTalk podcast episodes in their entirety on your computer or smartphone or viaApple PodcastsandGoogle Podcasts.

Dr. Fialkow:

Lets start out by talking about what would be risk factors that would make a woman more likely to get breast cancer? What are the things weve identified that we want to pay attention to?

Dr. Mendez:

The two main risk factors for breast cancer are being a woman and getting older. So, even though wed like to forget about breast cancer the older we get, the more concerned we need to be about it. To that, you can add other factors such as family history as well as some environmental factors, some hormonal factors, and some of those are modifiable and some are not.

Dr. Fialkow:

What would the average person be told to do regarding screenings, mammograms, etc.?

Dr. Mendez:

For an average woman with no significant risk factors, the recommendation is a baseline mammogram anytime between age 30 to 40, and, then, provided there are no abnormalities, an annual mammogram starting at age 40. And we know the denser the breast tissue, the more important it is to complement that with a breast ultrasound. Its part of doing a more thorough evaluation.

Dr. Fialkow:

You mentioned some of the non-modifiable risk factors, things you cant change. One is family history, which speaks to genetics. Can you unpack that a bit?

Dr. Mendez:

I want to make it clear that only 10 percent of breast cancers occur in women who have a family history of breast cancer and 5 percent have an identifiable mutation or something in the genetic makeup that really predisposes them to breast cancer. At the time of our initial consultation, or as part of our follow-up, we ask very specific questions about family history. Who was the relative? Is this your mother, your sister? Also we would want to know about any male breast cancer in the family or any other cancers in the family. We ask about ovarian cancer because thats related to the BRCA genes, which are the most prevalent genes associated with breast cancer. But we also ask about colon cancer, prostate cancer, pancreas, stomach cancer, because we know that certain genetic mutations are also associated with the gene. It helps us stratisfy the risk so we can determine who might benefit from a genetic consultation and actual genetic testing.

Dr. Fialkow:

If someone is high risk, what is the next step?

Dr. Mendez:

We have models to help us calculate. One that is most commonly used is the Tyrer-Cuzick Eighth Edition model, where it takes a lot of these factors in consideration. It gives us a percentage probability of that woman developing breast cancer within 10 years and during their lifetime. If someone indeed has high risk, usually greater than 20 percent, in addition to the increased surveillance, we will follow that patient with a breast MRI.

Dr. Fialkow:

During COVID-19 were seeing a decrease in women getting their mammograms. Can you speak to how important it is to maintain your screening, your routine screening process?

Dr. Mendez:

Its very important to maintain the screening. Early detection is key for improved outcomes and improved survival. In addition to screening, its important to know your family history and your body. I cannot underscore the importance also of breast self-exam. I can assure patients that the imaging centers are following COVID-19 guidelines in terms of safety. I encourage all women to go and seek their mammogram so that we can attend to their needs and continue with prevention.

Dr. Fialkow:

Can we talk a little about the Breast Cancer Prevention Clinic at Miami Cancer Institute?

Dr. Mendez:

In this clinic we are trying to identify a very specific patient population at increased risk of breast cancer because of their family history, certain pathologic conditions, previous radiation or because they have been identified to have some of these high-risk mutations. We will tailor a prevention plan, including genetic consultation if needed, and nutrition and exercise plans so that they can monitor all of the different components that are critical in order to maintain a healthy lifestyle. Instead of becoming a breast cancer survivor, they can continue as aprevivor. So thats a great concept.

Dr. Fialkow:

Theres also aBenign Breast Cancer Clinic. Could you speak a little about the benefit of that?

Dr. Mendez:

This clinic focuses on non-cancerous conditions. We make sure that in their clinical exam, everything is normal, as well as in their imaging. These are women who might be having breast pain or cysts or other benign conditions and need to be reassured by an expert so that they can move on, and, receive proper follow-up when needed.

Dr. Fialkow:

And how about survivorship programs?

Dr. Mendez:

Its not only about surviving the breast cancer, but also living your life with good quality and any adjustments. Currently in the United States we have 3 million breast cancer survivors because of all the advances and technology. We have a whole program of survivorship, everything from psychological support to yoga classes, to acupuncture, to nutrition and obviously healing. Whatever is needed to keep the patient not only cancer-free, but with great quality of life.

Tags: breast cancer, breast cancer awareness month, Miami Cancer Institute

Read more here:
Previvorship: How to Beat Cancer Before It Happens - Baptist Health South Florida

Recommendation and review posted by Bethany Smith

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic productsMore than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cellsIt is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regionsWithin these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domainPresently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

Read the rest here:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader

Recommendation and review posted by Bethany Smith

18-year-old Keely Campbell pays it forward by donating her stem cells 10 years after her dad's transplant. USA TODAY

Three-year-old Ava was constantly sick. Her gums were inflamed, and every time she got a scraped knee, it turned into a dangerous infection.

Her parents, Alicia and Jon Langenhop, were months pregnant with their third child when they learned that Ava's constellation of symptoms added up to an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. Although antibiotics and antivirals could prolong her life, the disease was considered fatal, usually before kindergarten.

Ava's primary hope, doctors told the Langenhops, was a bone marrow transplant from someone who was a good match, probably a brother or a sister.

Two-year-old Olivia had inherited the same disease as her big sister. She had been hospitalized with infections, too.

The baby in Alicias belly would be the girls best hope. Since both parents were carriers of the rare genetic mutation, the new baby, a boy, had a 25% chance of inheriting it, too.

Alicia was still in the hospital last October when they found out baby Landon had the mutation. Around the same time, the couple learned of a research trial in California.

Children Ava, Olivia and Landon Langenhop were diagnosed with an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. California Proposition 14, a citizen-initiated ballot measure, authorizes bonds continuing stem cell research.(Photo: Harrison Hill, USA TODAY)

Doctors would take each childs blood cells, fix the mutationand return them. It should be a permanent fix, with less risk than a bone marrow transplantbecause the healthy cells would be their own, so their bodies wouldnt reject them as foreign.

The approach had been tried in only one child, though.

This is the type of research reaching patients nearly two decades after President George W. Bush banned federal funding of stem cell researchand 16 years after California residents approved a tax increase on themselves to support research.

Proposition 14 on Tuesday's ballot askswhether Californians want to continue this work, providing $5.5 billion for stem cell research over the next three decades.

In the early 2000s, stem cell research was controversial because it often required the destruction of human embryos. Though embryonic stem cells remain essential for some therapies, in cases such as the Langenhops', treatment focuses on manipulating a persons own cells.

Stem cell science has made tremendous progress, but as in most new fields, the pace remains painstakingly slow. Every treatment has to be the subject of years of trial-and-error research, and many scientific hurdles linger.

Stem cells have been used to treat rare diseases, such as severe combined immunodeficiency, also known as "bubble boy disease," and they are being tested in more common conditions such as Parkinson's disease, macular degeneration, Type 1 diabetesand even heart disease.

"Even if a subset of stuff in the pipeline goes all the way, it will change the world for patients who currently don't have other good options," said Sean Morrison, a stem cell biologist in Dallas.

"It's a pivotal time in the field," said Dr. Deepak Srivastava, president of the Gladstone Institutes, a nonprofit research organization based in San Francisco. "We can feel that we're at an inflection point, where after years of discovery and creating a foundation of knowledge, we're finally at a point where a number of approaches are reaching clinical trials."

The Langenhop Family temporarily relocated from Canton, Ohio, to Los Angeles, so their children could receive stem cell treatment for leukocyte adhesion deficiency-1.(Photo: Harrison Hill, USA TODAY)

Stem cell therapies haven't advanced as far as some clinics offering expensive treatments claim.

Getting stem cells injected into your knee, for example, hasn't been scientifically proven safe or effective but some clinics charge thousands of dollars for the procedure.

"There are many clinics throughout the world,including in the United States, that continue to market unproven stem cell therapies," said Timothy Caulfield, a professor of law and public health at the University of Alberta in Canada. "They leverage the excitement that has surrounded this area to push products that aren't supported by good science. Indeed, there still aren't many stem cell therapies that are clearly ready for broad clinical application."

One way to distinguish the good science from the scams, Morrison said, is to look at what's promised. Anyone who offers to treat differentailments with the same "multipurpose" cells is selling snake oil, he said.

There are a wide variety of stem cells embryonic stem cells, induced pluripotent stem cells, somatic cells, etc, he said and it's challenging to figure out which to use against which disease.

"Every disease is a different set of challenges, and we spend years trying to develop therapies that are safe and effective," said Morrison, who chairs the public policy committee of the International Society for Stem Cell Research, a scientific organization. "When a company comes out making claims about a one-size-fits-all therapy that can treat everything, that's a sure sign that they're just trying to take your money."

Several researchers interviewed by USA TODAY said state funding helped put California at the forefront of global stem cell research.

George Daley, a stem cell biologist who is dean of Harvard Medical School, said he's envious of the California researchers who have access to this pot of money.

"California has always been a very exciting place to pursue science, but prior to (the taxpayer funding), it wasn't exactly the place that was the first on the tip of your tongue as a powerhouse community for stem cell science," he said. "But there's no way that today it wouldn't be listed in the top three."

Daley, a global leader in the field, said he thinks the funding spurred enthusiasm for stem cell research more broadly. "The entire excitement around the field of stem cell biology is part of the reason you're seeing cures in cancer and impending cures in devastating diseases like sickle cell anemia,"he said.

Although stem cell therapy hasn't gotten anyone out of a wheelchair yet, he said important research continues that may eventually transform paralyzed patients' lives. "If it's taken us longer than people anticipated, that's just the pace of science," he said.

Research begun in the Harvard lab of Doug Melton may soon revolutionize the treatment of Type 1 diabetes, he said, liberating patients from needing to inject themselves daily with insulin.

Srivastava, a cardiologist, admittedthat the field, backed by federal funding, spent more than a decade chasing cardiac stem cell treatments that never succeeded, possibly because they weren't stem cells at all.

Now, his lab and others have modified true stem cells into beating heart cells, he said, which should one day be able to restore tissue damaged by a heart attack.

The big bottleneck in the field, Srivastava said, is getting cells to fully mature in a dish. Scientists can turn stem cells into immature cells of many different types neurons, heart cells, retinal cells but they get stuck in this fetal-like state.

Beating heart cells derived from stem cells can create rhythm disturbances because they're electrically different from normal, mature cells, he said.

"It would be beneficial to have a cell that could function more like a cell after birth," Srivastava said.

Donald Kohn, the Langenhops' doctor at the University of California, Los Angeles, has been involved in stem cell research since 1985.

"I've seen it go from a dream, a vision, to now just various degrees of how it's working," said Kohn, also a member of the UCLA Broad Stem Cell Research Center. About a dozen blood diseases such as LAD-1 have shown "very good clinical responses" to the type of treatment the Langenhop children received.

The children are missing a proteinin their white blood cells that would allow the cellsto reach a cut or damaged tissue. The children can't clear infections and suffer from inflammation and other immune-related problems.

Kohn's study of kids with LAD-1 mutations will eventually include nine patients. Depending on the results, the companysponsoring the trial, Rocket Pharmaceutics of New York, will ask the U.S. Food and Drug Administration for a license to sell the therapy.

Donald Kohn, the Langenhops' UCLA doctor, calls the parents "heroic."(Photo: Harrison Hill, USA TODAY)

He said he's been blown away by how well the Langenhops have dealt with the trials and tribulations of the past year.

"I just think they're heroic, what these parents are doing," Kohn said.

At first, the Langenhops asked themselves how a disease that strikes fewer than 1 in a million children could have struck them three times.

But now, more than a year after Ava's diagnosis and six months after temporarily moving to California for the treatments, Alicia and Jon just want to bring three healthy kids home to Canton, Ohio.

They flew to California for the first time last December so doctors could collect bone marrow cells from Ava. They'd planned to come back in February for the treatment, but not enough cells had been repaired, so the February trip was just a repeat of December.

By the time they were ready to come back to UCLA Mattel Children's Hospital for her therapy in late April, the pandemic had struck. The airplane was nice and empty.

Ava Langenhop receives a stem cell treatment for an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesion deficiency-1.(Photo: Courtesy of UCLA)

Ava got chemotherapy twice a day for five days to kill off her faulty white blood cells. After a day of rest, she was given back her own blood stem cells, gene-edited to remove her damaging LAD-1 mutation.

Her one complaint: the therapy smelled like creamed corn and made her gag.

She recovered quickly, and after about a month in the hospital, enough white blood cells had grown back for her to safely return to the family's rental apartment, just off the UCLA campus, where her mom has turned the living room into a classroom for the girls.

Although she lost all her hair from chemo, it's slowly growing back, and she's very proud of her cropped hairstyle, Alicia said. She picks out a bow every day to match her outfit.

At Ava's three-month checkup this summer, doctors found her bone marrow was producing healthy white blood cells. Her LAD-1 is considered eliminated and she'll never need another treatment.

"She'll probably be healthy forever," Kohn said.

Landon, age 1, completed his treatment about a month ago and was allowed out of the hospital last week. He's bald, but his blue eyes still sparkle, and as he wavedthrough the camera on a recent Zoom call, it's hard to imagine a cuter, healthier-looking baby.

Although originally slated for treatment before her brother, Olivia, 3, ended up last because, as with her sister, the processing of her cells didn't work well the first time. She went to the hospital Sunday and starts her chemo Monday night. She is scheduled to receive the corrected cells next week.

Landon Langenhop receives his stem cell treatment for leukocyte adhesion deficiency-1.(Photo: Courtesy of UCLA)

Olivia was excited to start her therapy, to be "part of the club" with her sister and brother, Alicia said. "She can't wait to turn bald."

The cost of all three children'streatments and the rental apartment and plane fare are being picked up by Rocket Pharmaceuticals. That's the upside of volunteering for clinical trials: the treatment is paid for by the sponsor.

Jon was a bank branch manager before the pandemic and now works remotely for the same bank, reviewing loan applications. "It gives me the chance to be at the hospital with whichever child is in the hospital at that time," Jon said, chuckling.

Alicia, a former teacher and day care center assistant manager, has been home-schooling the kids since the start of the pandemic.

Their doctor hopes to have the family back in Canton for Christmas or at least New Year's. The weather won't be as nice as in Southern California, but they'll be home, surrounded by their supportive family and friends. And Jon and Alicia won't have to worry anymore about every scrape and sniffle.

They don't focus much on the details of how the science works. They're just happy it has.

"We feel so fortunate to be living in a time when this is possible," Alicia said.

If they had been in this situation even a few years ago, the treatment wouldn't have existed, Jon said. If they had found out about Ava's mutation when she was younger, they wouldn't have had two more children.

"It's kind of crazy how it's all worked out for us," he said.

The strength of their kids has given them strength. "They just go with the flow. It's kind of incredible how resilient they are and can just bounce back from these hospitalizations," Jon said.

"Like nothing ever happened," Alicia added.

The three children will probably have few if any memories of their disease and treatment. For Jon and Alicia, however, this year is seared into their memory.

"It'll take us a while to realize they don't have this anymore," Jon said.

Karen Weintraub can be reached at kweintraub@usatoday.com.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

The Langenhop Family plays at the Franklin D. Murphy Sculpture Garden at UCLA. Children Ava, Olivia and Landon were diagnosed with an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. California Proposition 14, a citizen-initiated ballot measure that will appear on the ballot in the 2020, authorizes Bonds continuing Stem Cell Research. A Yes vote will allow researchers to continue studying and working towards finding cures for individuals like Ava, Olivia and Landon.(Photo: Harrison Hill, USA TODAY)

Read or Share this story: https://www.usatoday.com/story/news/health/2020/11/02/stem-cell-therapy-californias-prop-14-seeks-tax-money-research-ucla/6049101002/

View post:
California Prop 14 would keep taxpayer funding of stem cell therapy research, which can change lives: Meet the Langenhop kids - AZCentral.com

Recommendation and review posted by Bethany Smith

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020. New data, from Cleveland Clinic, will be presented on the safety, efficacy and tolerability of CAEL-101 in combination with standard-of-care therapy in AL amyloidosis from the Phase 2 open-label dose escalation study that suggest early evidence of organ response. Data, from Caelum, that further demonstrate the safety and tolerability of CAEL-101 and support the selection of the 1000 mg/m2 dose for the Phase 3 study will also be presented.

The accepted abstracts are listed below and are now available on the ASH website:

Oral Presentation

Safety, Tolerability and Efficacy of CAEL-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients with AL Amyloidosis. Abstract #729. An oral symposium presentation is scheduled for December 7, 2020, 2:45 p.m. PST.

ePoster Presentation

CAEL-101 is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144), Abstract #2277 poster presentation, poster session II, December 6, 2020, 7:00 a.m. - 3:30 p.m. PST.

As was previously announced, the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101 in combination with standard-of-care (SoC) therapy in AL amyloidosis has begun. Enrollment is underway in two parallel Phase 3 studies one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease and will collectively enroll approximately 370 patients globally. The Phase 2 program continues with the addition of a study arm to evaluate CAEL-101 in combination with SoC therapy plus daratumumab.

About CAEL-101

CAEL-101 is a first-in-class monoclonal antibody (mAb) designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody is designed to bind to misfolded light chain protein and amyloid and shows binding to both kappa and lambda subtypes. In a Phase 1a/1b study, CAEL-101 demonstrated improved organ function, including cardiac and renal function, in 27 patients with relapsed and refractory AL amyloidosis who had previously not had an organ response to standard of care therapy. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis.

About AL Amyloidosis

AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded immunoglobulin light chains produced by plasma cells aggregate and form fibrils that deposit in tissues and organs. This deposition can cause widespread and progressive organ damage and high mortality rates, with death most frequently occurring as a result of cardiac failure. Current standard of care includes plasma cell directed chemotherapy and autologous stem cell transplant, but these therapies do not address the organ dysfunction caused by amyloid deposition, and up to 80 percent of patients are ineligible for transplant.

AL amyloidosis is a rare disease but is the most common form of systemic amyloidosis. There are approximately 22,000 patients across the United States, France, Germany, Italy, Spain and the United Kingdom. AL amyloidosis has a one-year mortality rate of 47 percent, 76 percent of which is caused by cardiac amyloidosis.

About Caelum Biosciences

Caelum Biosciences, Inc. (Caelum) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelums lead asset, CAEL-101, is a novel antibody for the treatment of patients with amyloid light chain (AL) amyloidosis. In 2019, Caelum entered a collaboration agreement with Alexion under which Alexion acquired a minority equity interest in Caelum and an exclusive option to acquire the remaining equity in the company based on Phase 3 CAEL-101 data. Caelum was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.caelumbio.com.

About Alexion

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: http://www.alexion.com.

[ALXN-P]

Forward-Looking Statement

This press release may contain forward-looking statements, including as such term is defined within Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, any statements relating to Caelums or Alexions growth strategy and our respective product development programs, plans related to clinical trials (including, commencement, completion and future patient enrollment), the anticipated benefits of CAEL-101 and any other statements that are not historical facts. Forward-looking statements are based on Caelum and Alexion managements current expectations and are subject to risks and uncertainties that could negatively affect each of our businesses, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks that CAEL-101 is not shown to be safe and effective in clinical trials or does not receive regulatory approval to be marketed, risks relating to each companys growth strategy; ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing (including, commencement, completion and future patient enrollment); risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on each Companys employees and consultants ability to complete work in a timely manner and on the ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; Caelums need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in each Companys SEC filings. Alexion and Caelum expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our respective expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 or any other protections afforded by applicable law. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Go here to see the original:
Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition - Business Wire

Recommendation and review posted by Bethany Smith

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1787<ype=S

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more:
Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over2017 2025 - Royal Sutton News

Recommendation and review posted by Bethany Smith

Legend has it that some of historys most beautiful women, including Marilyn Monroe and Elizabeth Taylor, shaved their faces. While this cant be substantiated, many of todays beauties are open about the benefits of shaving.

Every woman has facial hair. There are two types, vellus hair and terminal hair.

Vellus hair is the near-invisible peach fuzz that covers much of your face and body. Its role is to regulate temperature and evaporate sweat.

Vellus hair is very fine and translucent. If you scrutinize your face, especially in bright sunlight, you may be able to see vellus hair on your cheeks, forehead, upper and lower lips, neck, chin, and side burn area.

Terminal hair is darker and thicker. Some women have terminal hair along their upper and lower lips, sideburns, neck, and chin.

Facial shaving can be used to remove both vellus and terminal hair.

We go over the pros and cons of facial shaving for women, plus provide info on terminal hair growth and the conditions which might cause it.

In addition to removing hair, facial shaving can also be used as a mechanical (physical) exfoliator to remove dead skin cells. This can be a pro for some woman, but a con for others.

Before you take razor in hand, check out your skin. If you have conditions such as eczema, psoriasis, or acne, shaving may exacerbate irritation and discomfort. It may also lead to infection.

Sensitive skin, or skin that has red, irritated patches for any reason, may also not respond well to shaving.

If your skin is clear and can handle exfoliation, there are definite pros but also potential cons to shaving:

Shaving blunts the edges of hair, making it feel stubbly and coarse. This may create the illusion that hair has become darker or thicker.

Shaving facial hair, however, doesnt thicken it or change its color. It may make terminal hairs feel harder to the touch, until they grow out completely.

Facial shaving for women should be done differently than facial shaving for men. It also differs from the way you shave your legs and underarms.

To effectively shave your face:

Need the right facial razor? Here are two to buy online:

Other ways of removing facial hair include:

Unlike shaving which removes hair at the skins surface, waxing removes hair from underneath the skin, at the root.

It lasts longer than shaving, but carries some of the same risks such as causing ingrown hairs and skin irritation.

Waxing can be done at home, or in a salon by a professional. It can be uncomfortable or even painful for some people.

For waxing to work, hair has to be at least 1/4-inch long or else the wax cant grip it. If you have obvious terminal hair that youre self-conscious about, this may make waxing challenging to use on the face.

Laser hair removal is a long-lasting, semi-permanent solution for facial hair removal. It must be done by a professional, such as a dermatologist or licensed esthetician.

Laser hair removal can be expensive, but may provide many hair-free years for women with terminal facial hair, making it worth the expense for some.

Laser hair removal works by absorption of the laser within the hairs follicle. The pigment in hair attracts the laser beam to it, which is why its most effective in people with hair thats darker than their skin.

Since vellus hair is lightly pigmented and translucent, it cant be removed by laser.

Excess or dark facial hair can sometimes be the result of genetics. For example, certain ethnicities may include women that have more facial hair than others.

Medical issues and hormonal irregularities can also cause an overgrowth of facial hair to occur in women. These include:

If you have more than your fair share of facial hair, talking to your doctor may help provide additional insight and possibly medical solutions that will help alleviate the problem.

Facial shaving in women is more common than you might think. Its done to remove vellus and terminal hairs from the cheeks, chin, upper lip, and side burn areas.

Facial shaving also provides mechanical exfoliation, which can help skin look brighter and cleaner.

In order to shave your face effectively, you should use a tool designed specifically for this purpose.

If you have excess, dark hair on your face, there may be a medical or genetic reason behind it. In these instances, seeing your doctor may help to provide long-lasting solutions.

Read more:
Face Shaving for Women: Pros and Cons, Best Practice Tips - Healthline

Recommendation and review posted by Bethany Smith

AVONDALE, Ariz. Julie Giese doesnt like the spotlight, so this moment was awkward for her.

She was standing in the desert sun and smiling as a line of photographers snapped away, capturing pictures of both Giese the Phoenix Raceway track president and a car sporting the newly unveiled logo for NASCAR Championship Weekend.

This was March 6, before the pandemic arrived and turned 2020 into a giant barn full of cow dung, forcing the whole world to change its plans. That includes Phoenix, which will host its first championship race this weekend with limited capacity and a different feel than was originally envisioned.

Fortunately for NASCAR and the track, Giese knows all about dealing with giant barns of cow dung; after all, she grew up on a dairy farm in Wisconsin.

Yes, NASCARs lone female track president only the second ever is used to hard work, putting in long hours and accomplishing goals,...

Follow this link:
NASCAR's only female track president ready to host championship - The Athletic

Recommendation and review posted by Bethany Smith

Tracey Brown, Stacey Stewart, Angela Williams, Linda Goler Blount have created a Call to Action to ... [+] close the health gap for Black Americans.

For 20 years, Carol Fleming has lived with diabetes. In 2016, Fleming, who is now 66, joined Change Your Lifestyle, Change Your Life, a health-improvement program. Located in Flemings hometown of Detroit, Mich., the program was run by the Black Women's Health Imperative, a nonprofit organization created by and geared toward Black women to help protect and advance their health.

This program, among others at the Black Women's Health Imperative, is used to help Black women get healthy and address the underlying reasons for health disparities impacting their communities in America. Through advocacy on a federal level, the organization fights stereotypes about why diabetes, maternal mortality, breast cancer, and other often deadly, chronic health issues seem to plague the Black community.

"It's not in genes; it's due to systemic racism and bias that has created and still creates structural barriers for Black people in America to receive proper health care. Four hundred years of oppression, and what that has done to the way our bodies function brings us to where we are today," said Linda Goler Blount, the president, and CEO of Black Women's Health Imperative.

"These health disparities are what we should have expected based on the way people are treated and have been treated in this society, and where resources go and where they don't go and who has access and who doesn't."

Goler Blount and three other Black female CEOs for nonprofits in the health space are signaling a 'call to action' to address the health gaps for Black Americans. Currently, the health disparities impacting Black Americans, specifically Black women, are startling and have resulted in alarming statistics:

-Black women have three to four times higher rates of maternal mortality compared to white women. In New York City, its up to 12 times higher.

-Black Americans are 50 percent more likely to have diabetes and two and a half times more likely to die from the disease.

- Black women have a seven to eight times higher rate of diabetes, according to Goler Blount, and higher rates of mortality from diabetes, cardiovascular disease, and hypertension.

-Black women have 40 percent higher breast cancer mortality rates.

-Black women have, on average, about 15 percent more cortisol in their bloodstream than white women. Cortisol is a stress hormone. Elevated cortisol is associated with inflammatory and metabolic changes and raises the risk of diabetes, hypertension, and cardiovascular disease. The high cortisol in Black women is because of chronic racial and gender discrimination.

"These health disparities are unconscionable, and there is absolutely no reason for us to live this kind of reality," Goler Blount said. "It's going to take all of us to come together to speak truth to power about our lived experiences, and the impact of racism and gender discrimination on our health, and to apply the political pressure, and the moral pressure to change these systems."

Goler Blount argues the disparities can be found through the entire health system, from the person who works at the front desk of a doctor's office to the medical professionals themselves. She says an unconscious bias frequently results in Black women not being listened to; their fears and symptoms are often dismissed. Goler Blount also says Black women often receive less adequate care than their white counterparts, and they are often left out of clinical research studies. She even went as far as studying and co-publishing a paper on systemic racial bias in artificial intelligence in scheduling algorithms. Goler Blount found that hospitals and provider's scheduling systems were double and triple booking Black patients.

"The thing that everybody should contextualize about this, you know, if we pick something like breast cancer: in 1981, Black women and white women had the same breast cancer mortality rate. Well, what happened in 1981? We learned how to detect breast cancer; we learned how to treat it. So what we see now is a reflection of who had access and who didn't."

Keelee Moseley, a 40-year-old mother of three, says she believes systemic bias almost cost her life and her baby's life.

Keelee Moseley believes systemic bias almost cost her life and her baby's life.

In 2018, Moseley was pregnant with her third child. She went to an OBGYN checkup. The doctor noticed leakage, and her cervix was dilated. But Moseley was only 21 weeks pregnant.

"He said, you know, your pregnancy isn't viable. The baby is not going to survive," Moseley said. "He recommended abortion."

Moseley refused to accept that answer. She went home, where she spoke to her mother-in-law, who had been a nurse for decades, who recommended Moseley go the next morning to talk to an advanced maternal medicine doctor. The next day, she was admitted to the hospital on bed rest.

Moseley made it one more week before undergoing a cesarean section.

"He survived, you know, they didn't give him any chance," Moseley said. "And even when he was born, they said maybe you know, one percent chance of survival."

"But Adrian survived."

After the C-section, Moseley was in intense pain; but the doctors sent her home, saying the discomfort was normal. But the next day, it got even worse.

While Moseley and her husband were at the hospital visiting their newborn in the NICU, she began to feel lightheaded. Nurses took her temperature and discovered she had a fever. Moseley was taken to the ER and then back to Labor and Delivery, where they determined she had a high white blood cell count. Her stomach was swollen, red, and hot to touch. The hospital admitted her.

"I stayed the night, and I was still in a lot of pain. The second day it got worse, and I started to decline, Moseley said. "And then that evening, I vomited."

The doctor checked on Moseley, who explained her pain and symptoms. But the doctor said her stomach was swollen because it was irritated by her pajama pants that were too tight. He gave her Benadryl and left.

But Moseley believed something was more seriously wrong, so she kept taking photos of her swollen, red belly. And then, she found black blisters.

Doctors rushed Moseley into exploratory surgery. When she woke up, she was in the ICU with a large bandage around her stomach and a tube through her nose. She was informed her kidneys were failing and that she received multiple blood transfusions. The culprit was necrotizing fasciitis or a flesh-eating disease in her C-section incision.

Moseley spent over four weeks in the hospital recovering. Her baby was in the NICU for 144 days. She believes she wouldn't have been in this position undergoing multiple surgeries because of a flesh-eating disease had doctors taken her concerns seriously. She also believes if she were a different race, doctors would have worked harder to save her baby from the beginning, instead of first encouraging Moseley to have an abortion.

"I felt like, even if my voice wasn't enough, there were clinical signs that showed that I was in some distress and trouble," Moseley said. "And I felt like if doctors would have recognized that earlier, it may not have been so severe."

"Also, if I would have listened to my doctors, I would have never, never got to where I am today with Adrian. His birth was hard, but now he talks, he runs."

After some complications, doctors recommended Keelee Moseley have an abortion. Two years later, ... [+] Moseley's son is a thriving, healthy baby.

According to Stacey Stewart, the president and CEO of March of Dimes, there has been a maternal and infant health crisis for all women in the United States for several years. The U.S. is among the most dangerous developed nations in the world to give birth. But it is compounded and even worse for people of color.

Every year, Stewart says, 700-900 women die in the United States due to pregnancy and childbirth complications, and another 50,000 women come close to death in what are called 'near misses.' Black women die at a rate of three to four times compared to white women.

"We have had generations of systemic racism and discrimination that is embedded in the system. Black women often articulate that they don't feel respected and heard. Often, they present with symptoms, and their symptoms are dismissed. They are often not heard and not responded to in the same way that other women are," Stewart said.

"And then, of course, the pandemic comes, and then all these things are even more exacerbated."

The Covid-19 pandemic has disproportionately impacted Black and brown Americans, increasing the health inequity gap. According to AMFAR, the Foundation for Aids Research, as of August, 45 percent of Covid-19 cases, and 51 percent of Covid deaths, are in 22 percent of counties that are disproportionately Black. Black Americans are dying at more than twice the rate of white Americans from Covid-19.

Many of the reasons are related to social determinants of health like income, housing, food, and employment. A large percentage of Black Americans work what have become known as essential jobs - in the food industry, health services, etc. So while they may still have their job, it puts them at greater risk of getting sick. Many Black Americans would have to quit their job to protect their health, which puts them at greater risk for economic insecurity. Black Americans also often have health conditions, like diabetes and pre-existing conditions, that put them at greater risk.

But according to Goler Blount, we can't talk about the social determinants of health without talking about the inequalities that Black Americans have faced for decades, which are now being highlighted and made notably visible by the pandemic health crisis.

"The way people talk about data, they would lead people to believe that 'Oh, it's because they're Black [that they have a certain condition],' Goler Blount said. "Black women have 40 percent higher breast cancer mortality rates, and it's not because they're Black, it's the experience of being Black."

"Racism is the risk factor, and gender oppression is the risk factor."

Racism and gender oppression have significantly impacted the Black population in America when it comes to diabetes, according to Tracey Brown, the CEO of the American Diabetes Association. Brown, who has diabetes herself, says Black Americans and Hispanics are 50 percent more likely to have diabetes; she also says people of color are two and a half times more likely to die from diabetes.

"You can't talk about health in this country without talking about wealth wealth is health and you look at the number of people who are below the poverty line, 76 percent of those people are people of color," Brown said. "Genetics is a small portion of why people may have diabetes; the rest of the story is systemic racism and the social determinants of health."

"What we have to help people understand is we've got to attack these systems, these policies, these procedures if we want to seriously start to talk about changing health outcomes for people of color in this country."

Angela Williams, the CEO of Easterseals, a nonprofit that provides services for people with disabilities and their families, is advocating to improve Black disabled Americans' lives.

Black people with disabilities face higher rates of police violence and find themselves disproportionately impacted by the school-to-prison pipeline. Black children with disabilities often have their behaviors interpreted as aggressive and violent instead of a disability diagnosis. They also have a more challenging time getting access to much-needed early-intervention and services.

"What I want people to know is that we need to raise awareness, that this is, in fact, an American issue that must be addressed," Williams said. "Secondly, research institutions, corporations, and foundations must partner with organizations like Easterseals to solve these problems."

The American Diabetes Association, March of Dimes, The Black Women's Health Imperative, and Easterseals are all working towards changing policy and legislation at a federal level to improve Black Americans' lives and health.

At the Black Women's Health Imperative, they fund chronic disease prevention work across the country. They are working on policy with the Congressional Black Caucus and The Caucus on Black Women and Girls. They have also implemented anti-bias training for obstetric providers.

March of Dimes is instituting programs to reach moms at their homes through telehealth. They, too, created an implicit bias training program for healthcare providers and launched #BlanketChange, to demand policymakers, candidates for office, and community leaders take immediate action to fight for the health of all moms and babies.

The American Diabetes Association and Easterseals have advocated for change and improvements to Black Americans' healthcare through conversations with policymakers and spreading awareness on social media.

Meanwhile, Fleming, the woman from Detroit with diabetes, improved her health through the program at Black Women's Health Imperative. Today, she eats healthier and even walks three to five miles a day.

Carol Fleming has improved her health thanks to the Black Women's Health Imperative.

She is proud of how far she's come as an individual but says that, to see real change and improve all Black Americans' lives and health, there needs to be a societal overhaul.

"Doctors don't always believe that we're the same as people that are not of color," Fleming said. "I had always thought it was my genes, and I inherited diabetes from my family, and there wasn't anything I could do about it."

"But if you have diabetes, if you have heart problems, if you're obese, it's not something you have to take."

"We can fix this disparity through education."

Link:
Four Black WomenAll CEOsHave Created A 'Call To Action' To Close The Health Gap For Black Americans - Forbes

Recommendation and review posted by Bethany Smith

Parks Canada is looking into a conservation breeding program to increase Jaspers dwindling caribou population. Resource conservation manager David Argument said this has never been attempted before for southern mountain caribou. | Parks Canada/Layla Neufeld photo

Joanne McQuarrie, Local Journalism Initiative Reporter |reporter@fitzhugh.ca

With the Maligne herd extirpated and the Tonquin and Brazeau herds in Jasper National Park at dangerously low population levels, Parks Canada is looking at conservation breeding for caribou.

David Argument, resource conservation manager for Parks Canada, described the move as the only remaining suitable tool here for circumstances in Jasper.

He said: The work that weve been doing indicates the herds are too small and have been too small for some time, to rebuild naturally.

A well-developed proposal is being worked on, he said, and theres a timeline of several weeks and months as it goes through an expert review process.

Even with the urgency of declining populations, Argument emphasized the need to ensure the conservation breeding program will work before it is put in place.

Conservation breeding for caribou has actually never been attempted for southern mountain caribou, he said.

Its never been attempted on the scale were thinking will be necessary here in Jasper.

He added with low caribou numbers, bringing the animals into captivity has to be done correctly to ensure propagation of the species.

With the finalizing of the proposal a long way down the road, Argument said Parks Canadas attention is focused on working on retaining existing conservation measures that help to keep the remaining caribou persist on the landscape.

We know the numbers in Jasper are low, Argument said. The Tonquin herd is sitting around 45 animals and has been at that number for years. We survey that (area) annually and keep close tabs on how that herd is doing. We expect them to persist into the foreseeable future, barring some calamitous event which is possible with any wildlife population.

The last caribou in Banff National Park were declared extirpated when an avalanche killed the remaining five animals in an avalanche north of Lake Louise in 2009.

Argument said theres no reason to expect the Tonquin herd is going to follow the Maligne herd in the immediate future.

The Maligne herd, unfortunately, in reaching its end, got to lower numbers earlier and reached those lower numbers before the threats to caribou persistence were fully understood, and before the full suite of conservation measures we now have in place were developed, he said.

The Maligne herd is considered to have been at a functional extirpation level for quite a long time, because they havent had enough breeding females in that herd for a longer period.

The Tonquin herd we expect to persist and were not proposing any drastic measures in the immediate term, nothing that well take undertake this fall.

The number of breeding females is more important than the number of breeding males, Argument noted.

If there are below 10 breeding females in a herd, then theres a very small, very limited chance theyll be able to rebuild the herd naturally, he said.

There could be 100 bulls hanging around but if we have less than 10 breeding females then were in trouble. Thats what were really talking about when were talking about whether or not a herd is functionally extirpated.

About the conservation breeding proposal, Carolyn Campbell, Alberta Wilderness Association conservation specialist, said, As we understand, theres been quite a bit of expert review. If theyre going to do another review, make it quick and transparent.

We believe its time to tell Canadians. Make a decision. In any case, those caribou have no time to lose.

Addressing calls for change

The Alberta Wilderness Association (AWA) has called for Parks Canada to stop clearing snow beyond Maligne Canyon.

That and backcountry skiing, the AWA says, may inhibit potential caribou dispersal from the adjacent Tonquin or Brazeau ranges, and support wolf travel.

Argument said removing recreational opportunities is something that needs to be thought about fairly carefully in the national parks.

Argument said, Its not that the habitat is bad. Weve addressed the threats to caribou habitat in Jasper. Winter access restrictions are a significant part of that and those will remain wherever there are caribou present on the landscape.

We feel conditions are good right now: the predator density, the predator numbers are low, due in part to our management activities over the last 10 or 15 years.

In our view the conditions are actually very good in Jasper for the re-establishment of caribou herds.

Altering access

With the confidence that the Maligne herd is no longer there, Parks Canada has changed some access restrictions to the area.

Winter closures protect more than 3,000 square kilometres of winter habitat for caribou in Jasper National Park from November to March. The purpose of these closures is to prevent people from creating trails that wolves can use to prey on caribou in places that are otherwise inaccessible.

But this year, the boundaries of the closure in the Maligne Range have been changed, effective Nov. 1, to allow some limited opportunities for recreation.

Winter access has been opened to some terrain in the Bald Hills, and the area between Big Shovel and Little Shovel Passes is no longer restricted.

Travel along the Skyline Trail between Little Shovel Pass and the Bald Hills will not be permitted until after Mar. 1, 2021.

Even so, Campbell, AWA conservation specialist, said, Were concerned that the ongoing winter plowing and opening of trails still allows for early wolf access and wolf re-establishment in prime Maligne Valley caribou habitat.

We acknowledge the two trails are limited in area, and we appreciate that dogs are still not allowed, but we still think its urgent to end Maligne Road plowing.

Campbell said Parks Canadas decision to remove restrictions in those areas will make it hard to rescind them.

Parks Canada said that if caribou are observed in the Maligne Range, the closure will be reassessed and reinstated at any time.

Counting caribou

Argument said Parks Canada spend a great deal of effort surveying caribou, monitoring where they are actually living and the herd sizes that remain.

We have a pretty good handle on the numbers of each of these herds and where theyre spending their time, he said.

Argument said in the past, when the herds were larger, there would be natural distribution, also called natural immigration, between the herds. For example, 50 to 100 years ago, the Brazeau herd and the Maligne herd probably saw a lot of interchange of animals when their numbers were bigger, when the males were prospecting for different territory.

Now were in a situation where the Brazeau herd is down to 10 animals remaining and we know where theyre spending their time in the winters, Argument said.

Theres very, very little chance that those animals will naturally immigrate to the Maligne range to where the Maligne herd used to live. If that were to happen, well, wed be very excited to see that.

Argument said if that happens, Parks efforts would be put in place and any changes to how they manage visitor access would be put right back into the protection mode. Immediately.

He said although tracking collars have been used in the past to keep tabs on the number of animals, Parks Canada now uses less invasive tools.

Every year at about this time of year when we first get a good snow cover in the alpine areas, we fly in those areas so we can see the animal tracks, he said, adding that a survey was recently done in the Brazeau range and the caribou tracks stood out clearly.

Parks Canada staff go for the minimum count when they do surveys. Whatever number we come up with in that survey, we know with 100 per cent certainty that is the minimum number of animals remaining in that herd, Argument said. It may be that there are more, it may be that there are some that are not observed, some hiding in the trees.

That information is augmented by the skat DNA method, where skat is collected and sent to a genetics lab to make it possible to keep track of how many individuals are in that herd over the year. Skat is directly tied to the sex ratio male or female, an increase or decrease in the herd, age distribution.

In response to the COVID-19 crisis, Fitzhugh is now soliciting donations from readers. This program is designed to support our local journalism in a time where our advertisers are unable to due to their own economic constraints. Fitzhugh has always been a free product and will continue to be free. This is a means for those who can afford to support local media to help ensure those who cant afford to can get access to trusted local information. You can make a one-time or a monthly donation of any amount and cancel at any time.

Click on https://support.fitzhugh.ca for more information or to make your donation.

Thank you in advance for your support.

Link:
Breeding program 'being worked on' to boost caribou population in Jasper National Park Jasper's source for news, sports, arts, culture, and more -...

Recommendation and review posted by Bethany Smith

The Global Cell and Gene Therapy Market Report, published by Emergen Research, is an all-encompassing study of the Cell and Gene Therapy market, which emphasizes the estimated market size, share, value, volume, and futuristic outlook. The report details the major products and application rangesavailable in this market, highlighting the revenue, price, sales, production, growth rate, and market share of each segment and sub-segment. The essential market presented in the report in a tabular format is aimed at helping readers interpret the global market dynamics. The market intelligence report delivers a profound study of the Cell and Gene Therapy business domain, discussing its principal aspects, such as the import & export dynamics, production, consumption, sales channels, and consumer bases in the major regional segments. The global Cell and Gene Therapy market, which held a significant value of USD 1,180.0 Million in 2019, is projected to reach a whopping market value of USD 6,570.0 Million by 2027 at a stunning CAGR of 19.8 %.

The latest research report expounds on the profound impact of the COVID-19 pandemic on the global Cell and Gene Therapy market and its crucial segments. The report thoroughly examines the vital market-influencing factors and considers the COVID-19 pandemic as a major contributing element to this business verticals potential downturn. As per industry analysts, the Cell and Gene Therapy industry is currently reeling from the pandemics gripping effects, and remarkable changes have been observed in the market dynamics and demand trends over recent months.The financial strains being suffered by each business organization in this industry have significantly slowed down their progress. Additionally, the report assesses the pandemics overall impact on the global market growth and involves a future COVID-19 impact assessment to help readers make prudent business decisions.

Get a PDF sample copy of this report @ https://www.emergenresearch.com/request-sample-form/27

Key Players Participating in the Industry:

Spark Therapeutics LLC, Novartis AG, Gilead Sciences Inc., Bluebird Bio, GlaxoSmithKline, Celgene Corporation, Shire PLC, Sangamo Biosciences, Voyager Therapeutics, and Dimension Therapeutics

Emergen Research has segmented the global Cell and Gene Therapy Market on the basis of indication, vector type, and region:

Regional Fragmentation:

Request customization of the report @ https://www.emergenresearch.com/request-for-customization-form/27

The report succinctly analyzes the potential revenue growth of the Cell and Gene Therapy market, its development patterns, and the future market trends. Moreover, the research report specializes in the meticulous analysis of the present market scenario. It forecasts the market value, volume, drivers, restraints, demand and supply ratio, production capacity, import/export status, growth rate, and other critical aspects over the projected period.

The report offers a panoramic view of the Cell and Gene Therapy market on both global and regional levels. The study is further supported by key statistical data and industry-verified facts.The study strives to carefully gauge the present and future market growth prospects, untapped avenues, demand and consumption patterns, and the crucial factors poised to impact each market regions revenue potential. Therefore, the report scrutinizes the numerous growth trends & prospects and the significant challenges and threats that the market players might face in the upcoming years.

Target Audience of the Global Cell and Gene Therapy Market report:

Get this report at an incredible discount @ https://www.emergenresearch.com/request-discount-form/27

Full Coverage of the Report:

Get a broad analysis of the COVID19 impact on the Cell and Gene Therapy market @ https://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market

Thank you for reading our report. For further inquiry about customization, kindly get in touch with us, and our team will make sure the report is best suited for your needs.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Our expertise umbrellas the technological environment of all major industries, and our services help you map your actions to ensure optimal yield. Our analysts utilize their market proficiency to offer actionable insights that help our clients implement profitable strategies and optimize their return on investment. Our services are wide-ranging, right from technological environment analysis to technological profiling that highlights the existing opportunities in the market you can capitalize on to stay ahead of your competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

14671 110 Avenue, Surrey, British Columbia, V3R2A9

Emergen Research | Web: https://www.emergenresearch.com

E-mail: [emailprotected]

See the original post:
Global Cell and Gene Therapy Market to Record Significant Revenue Growth during the Forecast Period 2020-2027 | Spark Therapeutics LLC, Novartis AG,...

Recommendation and review posted by Bethany Smith